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Dementia is a clinical syndrome that is characterized by decline of cognitive 
function as well as behavioral and psychiatric disorders. The most prevalent 
subtypes of dementia include Alzheimer’s disease (AD), vascular dementia (VaD) 
and Lewy body dementia (LBD). Neuropathological hallmarks of dementia 
include abnormal deposition of misfolded proteins, neuronal and synaptic loss, 
and alterations of neurotransmitter systems.  
CNS Histaminergic H3 and Cannabinoid CB1 receptors are involved in cognition 
and memory functions not only through modulation of neurotransmitter release 
but also via direct downstream signaling. Previous studies have examined the 
status of H3 and CB1 receptors in AD patients (Medhurst et al., 2007, p. 
189254)(Lee et al., 2010). The expressions of H3 and CB1 receptors were 
significantly correlated with cognitive parameters, indicating their potential roles 
as novel therapeutic targets against AD. However, neurochemical characterization 
of H3 and CB1 receptors in patients suffering from other subtypes of dementia has 
not been performed. In this thesis, my experimental aim was to measure the status 
of H3 receptors in vascular dementia and mixed dementia, as well as CB1 
receptors in Lewy body dementia, using post-mortem human brain samples from 
longitudinally assessed cohorts. Receptor expression in multiple Brodmann areas 
was compared among disease groups and non-demented controls, and correlated 
with clinical and biochemical parameters. 
 xiv 
 
Cannabinoids have exhibited neuroprotective properties against Aβ pathology in 
both in vitro and in vivo models(Haghani et al., 2012a)(Fakhfouri et al., 
2012)(Esposito et al., 2006a). While a few pathways have been reported crucial 
for such modulation, the direct effect of Cannabinoid CB1 receptor agonists and 
inverse agonists on the cleavage process of amyloid precursor protein (APP) has 
yet to be elucidated. On the other hand, even though significant psychiatric side 
effects have limited their clinical applications(Topol et al., 14),Cannabinoid CB1 
receptor inverse agonists attenuate Muscarinic M1 antagonist-induced memory 
deficits(Wise et al., 2007)(Degroot et al., 2006), indicating a potential role of 
interaction between the two systems of G-protein coupled receptors in cognitive 
functions. It remains unclear whether CB1 inverse agonists may affect muscarinic 
receptor-mediated APP cleavage. In this thesis, my hypothesis is that CB1 inverse 
agonists may alter muscarinic receptor-related APP proteolysis toward the 
amyloidogenic direction. My results indicate that combined treatment with CB1 
inverse agonists and muscarinic agonist decreased the secretion of sAPPα in SH-
SY5Y neuroblastoma cell line when compared with muscarinic agonist treatment 
alone.  
By adding to the understanding of neurochemical alterations in dementia, my 
thesis may show how Histaminergic H3 receptors and Cannabinoid CB1 receptors 
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Alzheimer’s Disease and Cholinergic System 
1.1  Overview of Dementia 
1.1.1 Definition of dementia 
Dementia is a clinical syndrome which could be caused by various 
neurodegenerative and cerebrovascular diseases. Dementia is characterized by 
disturbance of higher mental functions such as memory, cognition and executive 
function, accompanied by impairment in social or occupational functioning.  
1.1.2 Diagnostic criteria of dementia 
The most updated standards for the clinical diagnosis of dementia are the Fifth 
Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5, 
www.dsm5.org) and the National Institute on Aging-Alzheimer's Association 
(NIA-AA) (McKhann et al., 2011).   
Among the clinical symptoms of dementia, loss of memory is often one of the 
earliest to occur. Demented patients may fail to retrieve memories from the past 
or from memories of new information, recognize family members or places they 
used to be familiar with.  Apart from memory problems, according to the NIA-
AA criteria, patients diagnosed to be demented must also have cognitive 
symptoms in at least two of the following five domains: 1) language functions, 2) 
formation and storage of new memory, 3) reasoning and making judgments, 4) 




1.1.3 Behavioral and Psychological Symptoms of Dementia 
Apart from cognitive and memory deficits, dementia patients may also frequently 
exhibit behavioral and psychological symptoms of dementia (BPSD) 
(International Psychogeriatric Association 1996). The term BPSD describes a 
series of non-cognitive symptoms commonly observed in dementia patients, such 
as psychiatric symptoms of anxiety, depression, delusion and hallucination, as 
well as behavior disturbances of agitation, restlessness, aggression, wandering etc. 
(Finkel et al., 1996). Clinical studies have suggested that over 50% of dementia 
patients suffer from at least one BPSD symptom (Margallo-Lana et al., 
2001)(Savva et al., 2009)(Haibo et al., 2013), and 90% of dementia patients will 
develop significant BPSD symptoms during disease progression (Finkel, 2003). 
BPSD may significantly lower the life quality of patients and their caregivers, as 
the symptoms could not only induce emotional stress, but also cause heavy 
financial burdens by increasing the likelihood of institutionalization. 
 
1.2  Overview of Alzheimer’s disease 
1.2.1 Discovery of Alzheimer’s disease 
As the most prevalent type of dementia, Alzheimer’s disease (AD) is named after 
Alois Alzheimer, a German psychiatrist who reported histological findings from 
the first case of AD in 1907. The patient exhibited progressive decline of 
cognitive functions in her early 50’s, with symptoms of memory loss, behavior 
abnormality and psychiatric problems. Using a novel staining method, Alois 
 5 
 
Alzheimer identified depositions of senile plaques and neurofibrillary tangles in 
her post-mortem brain, which had never been previously described. His findings 
established the diagnostic standard for this disease in aspects of both clinical 
manifestations and neuropathological hallmarks.  
1.2.2 Epidemiology and financial cost of Alzheimer’s disease 
Alzheimer’s disease is a progressive process of neurodegeneration, with age as a 
strongest risk factor (Kukull et al., 2002). The risk of developing dementia 
increases with age, particularly in the elderly population over the age of 65 years. 
Although AD patients may develop different patterns of symptoms with varying 
severity, with the progression of disease and exacerbation of symptoms, they all 
tend to develop requirements for caring services from family members or 
healthcare professionals. In recent years, the proportion of the aged population 
has been rapidly increasing in many countries, and the ever-growing number of 
AD patients has become an unprecedented challenge and a huge financial burden 
to governments and societies all over the world. 
As reported by the Centers for Disease Control and Prevention, USA, the 
population of people over 65 years old is estimated to double in the next 25 years 
and account for 20% of the entire US population by the year 2030. According to 
the report of Alzheimer’s Association (Thies et al., 2013), Alzheimer’s disease is 
currently the sixth leading cause of death in the general population, and is the fifth 
cause of death in the elderly population with ages over 65 in the United States. 
About 5 million people are affected by AD in the US, and by the year 2025 the 
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number of affected population is expected to reach 7 million. The monetary value 
of time spent on AD patient care, as contributed by millions of caregivers 
including family members and hospital workers, is considered to equal hundreds 
of billions of dollars every year.  
China is also confronted with a similar situation. As Chinese people now have a 
longer life expectancy but limited access to proper diagnosis and treatment, the 
number of AD patients in China is considered by the government to be highly 
underestimated and growing faster than expected. Even so, there were already 
more than 5 million patients diagnosed with dementia by the year 2010 (Chan et 
al., 2013). Based on a retrospective study in Shanghai, the annual cost of each AD 
patient was approximately 2,500 USD, which would make the overall cost a 
heavy financial burden on the country (Wang et al., 2008).  
Therefore, the exploration for effective treatments of AD remains extremely 
important, as the amelioration of symptoms and delayed deterioration of disease 
can reduce a large amount of expenditure and greatly improve the life quality of 
the elderly population worldwide. 
1.2.3 Clinical Stages of Alzheimer’s disease 
While every single AD patient may develop a unique pattern of disease 
progression, several clinical stages of AD can still be observed in the general 
disease population. As recommended in the diagnostic guidelines of AD set by 
National Institute on Aging (NIA) and Alzheimer's Association (AA), the time 
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course of AD can be defined into three stages: 1) Preclinical/early stage; 2) mild 
cognitive impairment (MCI) stage; 3) severe/dementia stage. 
1.2.3.1 Preclinical stage of Alzheimer’s disease 
Preclinical stage of AD is usually referred to as a period of time that subtle 
impairment of cognitive function may occur insidiously years before the actual 
emergence of clinical AD symptoms. In this stage, patients present minor memory 
deficits, as well as some behavioral and personality changes (Sperling et al., 
2011). Patients may develop gradual decline of cognitive functions, such as 
impaired abilities of short-term memory formation, decision making, orientation 
(about time, place and people), and fulfilling social or occupational 
responsibilities. Patients may also experience disturbed emotion and reduced 
motivation.  
Although in this stage, the symptoms may neither be severe enough to affect daily 
life activities, nor satisfy any diagnostic criteria of dementia or Mild Cognitive 
Impairment (MCI), the preclinical stage is still classified as part of AD, as it has 
been suggested that certain biomarkers in this stage could be related to higher 
risks of developing dementia in the future. For example, abnormal process of 
amyloidosis in the brain has been observed in people with normal cognitive 
function, showing biomarker alterations such as a reduced level of CSF Aβ42 and 
enhanced PET tracer retention of amyloid. These signs of brain Aβ accumulation 
may occur years before the clinical appearance of MCI or AD symptoms, and 
were correlated with disease severity (Jack et al., 2010). Also, biomarkers of 
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synaptic dysfunction were detectable by fMRI and FDG even in younger 
APOEgene ɛ4 allele carriers (Filippini et al., 2009)(Sheline et al., 2010, p. 4), who 
were at higher risk of developing AD.  
1.2.3.2 Mild cognitive impairment (MCI) stage 
With disease progression, patients may enter the mild cognitive impairment (MCI) 
stage where their cognitive and memory symptoms become relatively more 
noticeable. Patients develop greater difficulties in understanding, communicating, 
recalling newly acquired names or faces, making judgments and plans, or 
correctly performing calculations. Although these symptoms may not 
significantly impact daily living, patients may need more supervision and 
assistance in performing daily living activities. Behavioral and emotional 
disturbances of anxiety, depression, aggression, hallucinations and delusions may 
cause stress to both patients and their caregivers.  
1.2.3.3 Dementia stage of Alzheimer’s disease 
At this final stage of AD, patients develop dementia symptoms that are significant 
enough to impact daily living. As patients may fail to fulfill basic life activities 
such as eating or using the toilet, they require even closer observation and 
constant caring, and are likely to become bed-ridden. Stress level for both patients 





1.2.4 Subtypes of Alzheimer’s disease 
As about 90% of AD patients do not have a family history of AD and have 
relatively late onset of disease (>65 years of age), they are classified as ‘late-onset 
sporadic AD’. On the other hand, ‘early-onset AD’ accounts for 5 to 10% of AD 
patients who develop AD before the age of 65, and can be sporadic or familial. 
The familial type of early-onset AD is relatively rare and may occur during the 
age of 30’s or 40’s. The familial Alzheimer’s disease (FAD) is mainly caused by 
inherited genetic mutation in one of the following three genes: presenilin-1 gene 
PSEN1, presenilin-2 gene PSEN2 and amyloid precursor protein gene APP. 
Mutated presenilin proteins regulate the activity of γ-secretase and increase the 
amyloidogenic processing of APP (Duff et al., 1996)(De Strooper et al., 1998), 
promoting amyloid aggregation and accelerating disease deterioration. Mutations 
near the β-secretase cleavage site of APP increase secretion of Aβ and accelerate 
its deposition(Citron et al., 1992)(Haass et al., 1994).  
Sporadic late-onset AD is related to the APOE gene ɛ4 allele. Apolipoprotein E 
(ApoE) transports phospholipids and cholesterol out of the brain with the 
assistance of ATP-binding cassette transporter ABCA1(Hirsch-Reinshagen et al., 
2004). Different ApoE isoforms have been found to bind to Aβ with varying 
affinities. While the other isoforms bind to Aβ with higher affinity and are 
relatively more efficient in Aβ clearance (Tokuda et al., 2000)(Holtzman, 2004), 
the binding of ApoE4 to Aβ not only lowers its efflux opportunity but also 
promotes the formation of fibrils and deposition of Aβ peptides (Wisniewski et al., 




1.3 Neuropathological hallmarks of Alzheimer’s disease 
Over and above the neuropathology of normal ageing, dementia is associated with 
various neurodegenerative events, such as brain atrophy, degeneration of neurons 
and synapses, oxidative stress, neuroinflammation, as well as abnormal folding 
and deposition of proteins. 
Major neuropathological hallmarks include extracellular amyloid plaques, 
intracellular neurofibrillary tangles (NFT), neuronal loss and disrupted 
neurotransmission. NFTs are composed of hyperphosphorylated tau proteins, 
while amyloid plaques are mainly caused by enhanced abnormal processing of 









1.3.1.1 Amyloid precursor protein cleavage pathways 
Amyloid Precursor Protein (APP) is a type I transmembrane protein that can be 
cleaved in two alternative pathways under the mediation of three types of 
proteases: α-, β- and γ-secretase. Under physiological conditions, most of the 
proteolytic cutting of APP is initiated by α- secretase within the Aβ domain, 
releasing a soluble N-terminal fragment sAPPα into the extracellular space.  γ-
secretase then cuts within the membrane-bound C-terminal fragment (CTF). 
 12 
 
Alternatively, APP can be cleaved by β-secretase, releasing a relatively shorter 
soluble N-terminal fragment sAPPβ. The subsequent cleavage by γ-secretase 
releases Aβ peptides, with Aβ1-40 (~90%) and Aβ1-42 (~10%) as two most 
common types (Tran et al., 2002). Aβ42 is more prone to aggregate compared to 
Aβ40, thus is considered more pathogenic(Rochet and Lansbury Jr, 2000). 
1.3.1.2 Amyloid hypothesis of Alzheimer’s disease 
Genetic mutations, aging and neurodegenerative events may increase the 
proportion of APP cleaved under the β-secretase pathway. In physiological 
conditions, the most common Aβ peptide is Aβ40. However, studies of early-
onset familial AD suggested that mutated presenilins may increase β-secretase 
mediated APP proteolysis and result in a relatively higher ratio of Aβ42 to Aβ40 
(Kuperstein et al., 2010). Extracellular senile plaques, one of the key features of 
both normal ageing and AD, are composed mainly of aggregated Aβ peptides 
(Cras et al., 1991) 
The “amyloid cascade hypothesis of Alzheimer’s Disease” is generated from 
studies on the abnormal cleavage of APP, suggesting that enhanced 
amyloidogenic processing pathway of APP will lead to aggregation and 
deposition of Aβ peptides into amyloid plaques, which can initiate neurotoxic 
events and cause neuronal death in AD brains. Initially the aggregated 
hydrophobic fibrillar aggregates of Aβ peptides were considered to induce 
neurotoxicity, however some recent studies suggested that soluble oligomers and 
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diffuse ligands might serve as better indicators for disease severity (McLean et al., 
1999)(Karran et al., 2011). 
As α- and β- cleavage pathways are mutually exclusive of each other, α- pathway 
is considered ‘non-amyloidogenic’ because it precludes the generation of Aβ 
peptides from APP. Potential neuroprotective properties against Aβ pathology of 
sAPPα up-regulation have been widely studied (as described in 1.3.1.4). 
1.3.1.3 Neurotoxicity of Aβ 
The accumulative deposition of Aβ plays a crucial role in AD pathogenesis 
through various mechanisms of action: 
Inducing excitotoxicity: Aβ peptides disrupt neuronal calcium homeostasis, 
enhance environmental-induced calcium influx and increase intracellular calcium 
level, rendering neurons more vulnerable to excitotoxicity (Mattson et al., 1992). 
Exposure to Aβ makes neurons more susceptible to glutamate-induced calcium 
overflow and neurotoxicity (Mattson et al., 1992)(De Felice et al., 2007). 
Disrupting neurotransmission: Exposure of β-amyloid peptides disrupt 
muscarinic signal transmission by uncoupling muscarinic receptors from G 
proteins(Kelly et al., 1996), inhibit cholinergic-mediated generation of long-term 
potentiation (LTP) and also reduce synaptic plasticity (Lambert et al., 1998).  
Inducing neuroinflammation and stimulating oxidative stress: While 
neuroinflammatory cytokines (IL-1β, TL-6, TNF-α) may reduce sAPPα level and 
promote Aβ pathology (Blasko et al., 1999), many studies have suggested the 
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involvement of Aβ in stimulating neuroinflammation and oxidative stress. The 
localization of Aβ plaques near reactive microglia has been observed(Itagaki et al., 
1989). Microglia may attach onto the surface of Aβ deposits and trigger the 
production of reactive oxygen species (ROS)(El Khoury et al., 1996), or even kill 
the neurons exposed to Aβ under the mediation of lipopolysaccharide (LPS) 
receptor CD14 (Bate et al., 2004).While oxidative stress may up-regulate 
intracellular Aβ (Misonou et al., 2000), Aβ can induce lipid peroxidation and 
protein oxidation in the brain, which is known to have a rich distribution of 
polyunsaturated fatty acids (PUFAs), proteins, lipids and nucleic acids but limited 
amount of anti-oxidants (Glabe, 2001)(Barnham and Bush, 2008). Various 
markers of oxidative stress have been observed to localize near or within amyloid 
plaque depositions, such as DNA damage, lipid peroxidation-induced membrane 
penetration, as well as oxidation and glycation of proteins (Matsuoka et al., 
2001)(Mecocci et al., 1994). Aβ can also enhance the production of free radicals 
and ROS by disrupting neuronal homeostasis of metal ions (e.g. copper, zinc and 
iron) and reducing the bridging effect of superoxide dismutase-like histidine 
residues (Curtain et al., 2001). 
1.3.1.4 Neuroprotective effects of sAPPα enhancement 
As proteolytic metabolites of APP cleaved under different secretase pathways, the 
production of sAPPα and sAPPβ are mutually exclusive of each other, which 
leads to the hypothesis that up-regulation of sAPPα is beneficial in suppressing 
Aβ toxicity. Apart from direct inhibition of amyloidogenic cleavage of APP, 
sAPPα is also involved in various neuroprotective and proliferative activities, 
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such as exhibiting neurotrophic benefit, promoting neurogenesis and neuronal 
differentiation, sustaining synaptic plasticity, protecting against neurotoxicity and 
apoptosis.  
Protection against neurotoxicity: In APP-transgenic mouse model, 
overexpression of ADAM10 (α-secretase) induced up-regulation sAPPα secretion, 
which led to significantly reduced amyloid plaque formation, as well as 
amelioration of LTP formation inhibition and cognitive deficits (Postina et al., 
2004). It has been observed that sAPPα is able to activate potassium current, 
suppress gluatamate-induced NMDA current and Ca
2+
 overflow, and thus protect 
neurons and maintain synaptic plasticity in conditions of excitotoxicity (Furukawa 
and Mattson, 1998).  
Neurotrophic and survival-promoting effect: sAPPα also exhibits a 
neuroprotective role in activating several survival-promoting signaling pathways 
including PI3K/Akt-GSK3β (Jimenez et al., 2011), p42/p44 (ERK1/ERK2) 
mitogen-activated protein (MAP) kinases, NF-κB (Cheng et al., 2002), p38/ 
myocyte enhancer factor-2 (MEF2) pathway (Burton et al., 2002), etc. In vivo 
injection of certain sAPPα peptide domains was able to significantly reduce post-
traumatic impairments of cognition and motor function in a rat model, possibly 
through the interaction with heparan sulfate proteoglycans (HSPGs), one 
component of extracellular matrix found to stimulate neurite growth when acting 
as an sAPPα binding substrate (Corrigan et al., 2011)(Clarris et al., 1997).  
 16 
 
Promoting neurogenesis and neuronal differentiation: sAPPα promotes neurite 
growth and neural stem cell differentiation(Turner et al., 2003)(Kwak et al., 
2006)(Caillé et al., 2004), possibly due to their structural similarity with certain 
growth factors and activation of growth factor receptors, as well as stimulation of 
MAPK-related signaling molecules(Gakhar-Koppole et al., 2008). 
1.3.2 Neurofibrillary tangles 
 






Neurofibrillary tangles (NFTs) are abnormal aggregations of hyperphosphorylated 
tau proteins. Tau is a type of soluble microtubule-associated protein (MAP) that 
binds with and stabilizes microtubules, and promotes the polymerization of 
tubulins into microtubules. In AD brains, tau proteins become abnormally 
hyperphosphorylated at serine/threonine phosphorylation sites(Buée et al., 2000), 
rendering their association with microtubules unstable. Some tau proteins 
disintegrate from microtubules, twist and form “Paired Helical Filaments (PHFs)” 
which eventually assemble and aggregate into insoluble neurofibrillary tangles 
(Kosik et al., 1986). Intraneuronal aggregations of fibrillary tangles of tau lead to 
instability of cytoskeleton and disruption of axonal transport, resulting in synaptic 
dysfunction and neuronal death(Buée et al., 2000). NFTs are commonly present in 
the cortex and hippocampus of AD brains. 
 
1.4 Therapeutic strategies and hypotheses of treating Alzheimer’s disease 
1.4.1 Targeting neurotransmitter systems 
Currently there are only two categories of medications approved for treatment of 
Alzheimer’s disease: Cholinesterase inhibitors (ChEIs) and glutamatergic receptor 
antagonist Memantine. Both are designed to modulate specific neurotransmitter 
systems, the cholinergic system and the glutamatergic system.  
The mechanism of ChEIs will be elaborated in the subsequent section 1.5. 
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Glutamate is the major excitatory neurotransmitter in the human brain involved in 
physiological neuronal activities like long-term potentiation (LTP), learning and 
memory. Two types of glutamate receptors have been identified: AMPA receptor 
and M-methyl-D-aspartate (NMDA) receptors, both of which are ion channels, 
with NMDA receptors exhibiting better permeability to calcium(Choi, 1992).  In 
neurodegenerative diseases, glutamate receptors tend to be over-activated, 
resulting in a massive influx of calcium. Up-regulated intracellular level of 
calcium may impair mitochondria functions, produce reactive oxygen species and 
induce cell apoptosis(Hynd et al., 2004). As a non-competitive antagonist for 
glutamate NMDA receptors, Memantine blocks excessive calcium influx and 
protects against glutamate-mediated excitotoxicity. Clinical trials of Memantine 
in dementia patients have shown good tolerance and improvement of cognitive 
symptoms(Winblad and Poritis, 1999).  
1.4.2 Targeting amyloid pathology 
Multiple therapeutic strategies targeting amyloid pathology have been 
experimentally investigated in animal models and clinical trials, such as: 1) 
activating α-secretase(Fisher et al., 2002); 2) inhibiting β-secretase(Asai et al., 
2006)(Hussain et al., 2007) or blocking the β-secretase cleavage site of 
APP(Rakover et al., 2007); 3) inhibiting γ-secretase(Siemers et al., 
2006)(Anderson et al., 2005, p. -299897); 4) vaccination against Aβ and 
enhancing Aβ clearance(Janus et al., 2000)(Bayer et al., 2005)(Masliah et al., 
2005). The effect of γ-secretase inhibitors remains controversial, with not only 
minimal improvement but also unwanted peripheral and CNS side effects, 
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probably because the inhibition of γ-secretase may affect its cleavage processing 
of other proteolytic substrates, such as Notch (Fleisher et al., 2008)(Siemers et al., 
2006)(Imbimbo and Giardina, 2011). β-secretase inhibitors have been brought 
into early clinical trials, while structural design and synthesis of new candidates 
are still ongoing(Ghosh et al., 2012). 
1.4.3 Targeting neuroinflammation and oxidative stress 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to reduce 
the incidence and alleviate symptoms of AD(Stewart et al., 1997) by suppressing 
microglia activation and decreasing inflammation-induced neurotoxic molecules 
such as cytokines, adhesion molecules and free radicals. Yet a favorable 
protective effect of NSAIDs seems to require drug administration before the onset 
of dementia as well as long-term usage(Zandi et al., 2002). 
Various indicators of oxidative stress, such as increased protein 
oxidation(Schippling et al., 2000), high production of free radicals(Markesbery, 
1997) and relatively low level of vitamins(Lopes da Silva et al., 2013), have been 
related to Aβ accumulation and cognitive impairment. Vitamins and antioxidants 
extracted from natural plants have been tested in clinical trials of AD. However 
their effect as therapeutic supplementary remains to be elucidated, as a number of 
studies have reported insignificant improvement of cognitive symptoms (Sano et 





1.5 Cholinergic system and Alzheimer’s disease 
1.5.1 Cholinergic neurotransmitter system 
The cholinergic system is one of the major neurotransmitter systems in the central 
nervous system. Most cholinergic neurons originate in the basal forebrain, 
especially the nucleus basalis of Meynert (NBM), and project widely through the 
cerebral cortex and the hippocampus which play crucial roles in learning, memory 
and other higher mental functions.  
The neurotransmitter acetylcholine (ACh) is synthesized from choline and acetyl 
co-enzyme A (acetyl-CoA) under the catalyzing effect of Choline 
acetyltransferase (ChAT). The synthesized ACh is uptaken by the vesicular ACh 
transporter (VAChT) and stored into neuronal terminal vesicles. Upon neuron 
activation, calcium ions induce the docking and fusion of vesicles onto neuronal 
terminal membrane, releasing ACh into the synaptic cleft. ACh binds to 
postsynaptic cholinergic receptors (e.g. Muscarinic M1 and M3 receptors) and 
induces cholinergic neurotransmission. Dissociated ACh from post-synaptic 
terminals as well as unbound ACh will then either be hydrolyzed back into 
choline and acetyl-CoA, or be re-uptaken for recycling.  
There are two major groups of cholinergic receptors, with muscarinic receptors 
being G-protein coupled receptors and nicotinic receptors being ionotropic 
receptors. 
Nicotinic receptors are expressed in both neuromuscular junctions and brain 
neurons. CNS nicotinic receptors are located on presynaptic, peri-synaptic and 
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extra-synaptic sites, acting as ligand-gated cation channels (Itier and Bertrand, 
2001). Permeability of nicotinic receptors to calcium is involved in synaptic 
excitability and neurotransmitter release. The potential therapeutic value of 
nicotinic receptor ligands has been explored in treating neurodegenerative and 
neuropsychiatric disorders, such as nicotinic receptor agonists providing 
neuroprotection against amyloid toxicity(Kihara et al., 1997), ameliorating 
attention deficit hyperactivity(Wilens et al., 1999) and schizophrenia 
symptoms(Adler et al., 1992). However nicotinic receptor agonists targeting the 
CNS can be of low selectivity and limited efficacy while inducing CNS and 
gastrointestinal side effects (Lam & Patel 2007)(George et al., 2008). Currently 
only a few nicotinic receptor ligands have been officially approved as disease 
medication (e.g. Bupropion and Varenicline for smoking cessation)(Lam and 
Patel, 2007). 
1.5.2 Muscarinic G-protein coupled receptors 









G-protein coupled receptors (GPCRs) are constituted of a large family of 
receptors, also known as “seven-transmembrane domain receptors”, integrated in 
cell membrane and bound to G-proteins. GPCRs are able to sense and bind with 
extracellular ligands, interact with G-protein and activate intracellular signaling 
transductions.  
G-protein (GTP-binding heterotrimeric G protein) consists of three subunits: Gα, 
Gβ, and Gγ, among which Gβ and Gγ are inseparable as the Gβγ complex. When 
G-protein bound receptors are not activated, Gα and Gβγ are assembled together 
in resting state, and Gα is bound with guanosine diphosphate (GDP). Stimulation 
of GPCR catalyzes conformational changes of the Gα subunit, which then works 
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as a guanine nucleotide exchange factor to replace GDP with guanosine 
triphosphate (GTP). As the Gα(GTP)- Gβγ complex becomes unstable, they 
separate from GPCR and split into Gα(GTP) subunit and Gβγ complex, initiating 
downstream signaling. Gα itself will subsequently catalyze the hydrolysis of GTP, 
turning itself back into the inactivated GDP bound form, which then reassociates 
with a free Gβγ dimer, restoring the inactive state of G-protein and terminating 
downstream effects.  
GPCRs can be activated by various kinds of external ligands and trigger complex 
downstream signaling transductions. Neurotransmitters (acetylcholine, GABA, 
dopamine, adenosine, glutamate, serotonin etc.), neuropeptides, growth factors, 
cytokines and chemokines are able to stimulate different subtypes of GPCRs. 
 The type of downstream signaling initiated by a GPCR is decided by the type of 
G-protein it is linked with. Heterotrimeric G proteins are grouped by different Gα 
families, each family activating different cascade of second messengers and 
downstream effectors. Most well studied Gα subtypes include Gαi/o, Gαs, and 
Gαq/11. 
The most well characterized effect of Gi/o and Gs proteins is the 
activation/inhibition of adenylate cyclase, which controls the production of cAMP 
from ATP. The interaction between cAMP with PKA, which further stimulates 
signaling molecules like src and Rap, is the biochemical basis for many 
physiological and neuronal activities.  
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Gαq/11mainly activates PLCβ, which induces the cleavage of PIP2 into second 
messengers DAG and IP3. These molecules modulate the function of calcium 
channels as well as control the activation and phosphorylation of downstream 
signaling messengers including PKC and MAPK/ERK. 
 










1.5.2.2 Muscarinic GPCRs 
Subtypes of muscarinic receptors have been well characterized, among which M1 
and M3 receptors act as postsynaptic Gq protein coupled receptors in the CNS, 
while M2 and M4 receptors are coupled to Gi/o proteins(Migeon et al., 1995).  
Through application of Muscarinic M1 receptor agonists, animal studies have 
established the direct modulatory role of postsynaptic M1 receptors in learning 
and memory(Levey, 1996)(Anagnostaras et al., 2003). The selective M1 receptor 
antagonist Scopolamine, on the other hand, impairs the performances of animals 
in tests of memory acquisition and retention, attention and orientation (Calhoun 
and Smith, 1968)(Flood and Cherkin, 1986)(Broks et al., 1988). Postsynaptic M1 
receptors have been reported to be preserved in AD brains(Flynn et al., 1991)(Lai 
et al., 2001). However, the postsynaptic M1 receptor-related downstream 
signaling pathways (e.g. PKC pathway(Tsang et al., 2007) seem to be impaired, 
possibly due to the receptor’s uncoupled status from G protein. 
Besides M1 receptors, M3 receptors have also been related to cognitive and 
memory functions. M3 knock out mice exhibited significant deficits in fear 
conditioning learning and memory(Poulin et al., 2010). Stimulation of M3 
receptors in SK-N-SH human neuroblastoma cell line enhanced signaling 
pathways that are beneficial for cell viability, e.g. ERK1/2 and CREB 
phosphorylation (Greenwood and Dragunow, 2010), indicating neuroprotective 




1.5.3 Cholinergic enhancement as AD therapy 
It is well supported by studies that the cholinergic system plays an important role 
not only in normal brain function of cognition and memory, but also in 
neurodegenerative disease pathology.  
Characterization of cholinergic system in postmortem brain tissues of AD patients 
has suggested the occurrence of cholinergic loss in the early stage of the 
disease(Bowen et al., 1982). Degeneration of basal forebrain cholinergic neurons, 
reduced synthesis and release of acetylcholine, impaired ChAT activity, as well as 
loss of receptors due to brain atrophy, have been described in AD brain areas like 
cortex, hippocampus, amygdala, etc.(Kasa et al., 1997)(Francis et al., 1999), and 
are related to intellectual impairment(Perry et al., 1978) and dementia 
severity(Wilcock et al., 1982). 
Based on these findings, the “cholinergic hypothesis” has been proposed, that the 
hypofunction of cholinergic neurotransmission contributes to the impairment of 
memory and cognition in AD, and that restoration of cholinergic function can 
ameliorate dementia symptoms. However, clinical trials using direct muscarinic 
receptor agonists have shown limited efficacy and absence of overall 
improvement in AD patients(Mouradian et al., 1988)(Bruno et al., 1986), which 
was later found to be related to the impaired coupling status of muscarinic 
receptors to G-proteins(Warpman et al., 1993)(Joseph et al., 1993)(Tsang et al., 
2006). The disturbance of M1 receptor coupling to G-proteins was correlated with 
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dementia severity(Tsang et al., 2006) and may contribute to the limited clinical 
improvement effects of muscarinic agonists in AD patients. 
Currently acetylcholinesterase inhibitors (AChEIs), including Rivastagmine, 
Galantamine, Donepezil and Tacrine, are the only groups of medications officially 
approved and licensed for treatment of AD besides NMDA receptor antagonist 
Memantine.  AChEIs up-regulate acetylcholine level and facilitate cholinergic 
transmission by inhibiting the activity of acetylcholinesterase (AChE) and 
decreasing the breakdown of the neurotransmitter acetylcholine. In clinical trials, 
AChEIs have shown moderate symptom-ameliorating effects on not only 
cognitive dysfunctions(Birks, 2006) but also behavioral disturbances(Gauthier et 
al., 2002) of AD patients.  
Although AChEIs are commonly used and efficacious, their symptom 
ameliorating effects are usually moderate. Firstly, the cholinergic system might 
not be the only neurotransmitter system involved in neurodegenerative pathology 
and is disrupted by AD pathology, thus specifically targeting cholinergic system 
alone may not bring substantial improvement of symptoms; secondly, the 
enhancement of cholinergic transmission by AChEIs still cannot restore the 
impaired cholinergic downstream signaling induced by G-protein uncoupling.  
1.5.4 Aβ and cholinergic system 
As one of the major pathological hallmarks of AD, Aβ has been observed to 
induce neurotoxicity, damage neuronal function and impair neurotransmission 
such as cholinergic signaling(Tran et al., 2002). Aβ pathology inhibits 
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hippocampal release and uptake of endogenous ACh(Kar et al., 1998). Low 
concentration of Aβ suppresses ACh synthesis in cholinergic neurons(Takashima, 
1997). 
On the other hand, as the production and processing of APP are regulated by 
neuron activity, the proteolytic metabolism of APP is also regulated by 
neurotransmitter systems, including the cholinergic system(Nitsch, 1996). The 
activation of Muscarinic M1/M3 receptors shifts the APP cleavage process toward 
the non-amyloidogenic side, up-regulating sAPPα production and inhibiting β- 
secretase activity via MAPK-ERK and PKC related mechanisms. Application of 
both muscarinic agonists and cholinesterase inhibitors up-regulate sAPPα, reduce 
Aβ production and alleviate Aβ induced neurotoxicity in cell lines and animal 
models (Fisher, 2007)(Hock et al., 2000)(Gu et al., 2003)(Li et al., 2010). The 
protective effect against Aβ pathology may add to the value of the cholinergic 































Vascular Dementia and Mixed Dementia 
2.1 Definition of vascular dementia 
Vascular dementia (VaD) is dementia caused by disrupted supply of blood to the 
brain, which is often induced by cerebrovascular events, such as multiple small 
strokes or sometimes a large stroke accompanied by small strokes. VaD is 
currently recognized as the second most prevalent type of dementia after 
Alzheimer’s disease(Kalaria et al., 2008). VaD often occurs after a clinical stroke, 
and patients may experience a sudden worsening of cognition, with a typical 
stepwise pattern of cognitive deterioration (condition stays at a certain level 
before the next sudden worsening) as well as neurological signs of focal 
infarction(Erkinjuntti et al., 2004).  
2.2 Major subtypes of vascular dementia 
VaD can result from ischemic, hypoperfusive or haemorrhagic events in the brain, 
among which different pathological conditions may induce clinical presentations 
of multiple subtypes, which differ in the number, size and location of lesions. 
For example, occlusions or infarctions in large vessels may lead to multi -
infarct/single-infarct dementia. Multi-infarct dementia (MID) is caused by 
multiple embolic or thrombotic occlusions in medium to large size arteries, 
resulting in multiple infarcts, lacunes and microinfarcts(Hachinski et al., 1974). 
Single-infarct dementia is usually related to one single stroke that causes infarct in 
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several functional regions of the brain such as thalamus, occipital lobe and 
hippocampus(Tanaka et al., 2012)(Auchus et al., 2002).  
Apart from large-vessel vascular dementia, diseases in small sized arteries may 
cause various subtypes of small-vessel vascular dementia(Roman et al., 2002), in 
which subcortical ischemic vascular dementia (SIVD)  is a relatively prevalent 
and homogenous type. Blood vessel hypoperfusion and ischemia may cause SIVD 
patients to suffer from complete or incomplete infarcts in the white matter, as well 
as disrupted connections between prefrontal cortex and the subcortical areas. 
While vascular dementia pathologies are mostly due to cerebrovascular diseases, 
the co-existence of Alzheimer’s disease is commonly observed. The term ‘mixed 
dementia’ is usually used to clinically describe the combined pathology of AD 
and VaD.  
2.3 Diagnosis of vascular dementia 
According to the NINDS-AIREN criteria(Román et al., 1993), an important 
standard for the diagnosis of probable VaD is the temporal relationship between 
symptomatic occurrences of dementia and cerebrovascular disease: patients 
develop dementia symptoms within 3 months after a stroke, with either sudden 
deterioration of cognitive functions, or fluctuating, stepwise worsening of 
cognition. Deficits in memory and at least two cognitive domains need to be 
confirmed with clinical and neurological assessments and have to be severe 
enough to affect activities of daily living, without considering the effect of stroke. 
Also, VaD patients may exhibit large-vessel infarcts, single-strategic infarcts, 
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multiple lacunes in basal ganglia and white matter, or extensive periventricular 
white matter lesions in neuroimaging examinations. Similar to stroke patients, 
VaD patients may develop focal deficits including hemiparesis, facial weakness, 
Babinski's sign, loss of sensory function, blindness in one or both eyes, and 
difficulty in making speeches(Staekenborg et al., 2008). Other clinical features of 
VaD include gait disturbance, urinary problems, changes in mood or personalities 
etc. 
The diagnosis of mixed dementia has been difficult due to its high heterogeneity 
of clinical and neuropathological presentations, lack of generally accepted and 
standardized diagnostic criteria and limited diagnosis accuracy. As mixed 
dementia patients may have both vascular pathologies (large or small infarcts, 
lacunes, white matter lesions) and AD hallmarks (e.g. plaques and tangles), 
cerebrovascular deficits are likely to interact synergistically with AD pathology, 
causing deterioration of cognitive functions(de la Torre, 2002)(Jellinger, 2008). 
Clinical studies have suggested that the actual percentage of “pure” AD in the AD 
population might be lower than expected, as many patients showed CNS burdens 
of mixed AD and CVD pathology(Lim et al., 1999)(Nolan et al., 1998)(Fernando 
et al., 2004). It can be speculated that concomitant pathology of AD and VaD can 
be more prevalent than previously identified. As the risk of developing dementia 
and/or cerebrovascular deficits increases with age, mixed dementia will become 




2.4 Risk factors for vascular dementia 
As VaD is related to or caused by cerebrovascular disease, VaD has been 
suggested to share many risk factors with stroke. 
A higher risk of developing VaD can be related to older age, male gender, lower 
level of education, and certain ethnic groups(Gorelick, 1997). The number, size 
and location of stroke-induced infarctions as well as degree of brain tissue atrophy 
are also considered as predictors for VaD. Other factors include hypertension, 
smoking, diabetes and a high level of cholesterol(Hayden et al., 2006). 
2.5 Pharmacological therapies for vascular dementia and mixed dementia 
Although the clinical symptoms of VaD patients are often similar to those of AD 
patients, such as impaired cognitive function and memory as well as changes in 
mood and behavior, VaD is not caused by AD pathologies of amyloid plaques or 
neurofibrillary tangles, but rather related to the disrupted blood supply to the brain 
in cerebrovascular diseases. When a patient’s brain suffers from either chronic 
block of oxygen and nutrients or an acute attack of stroke, massive cell death can 
be induced, impairing brain function. Though treatments are available for stroke 
symptoms and the cognitive symptoms can be ameliorated over time if given 
proper treatment, many patients still suffer from a progressive worsening of 
cognitive function.  
Currently there are no widely approved treatments for vascular dementia patients. 
In order to slow down disease progression, VaD patients are usually advised to 
control cerebrovascular risk factors (hypertension, high cholesterol, smoking etc.). 
 34 
 
Traditional AD medications like cholinesterase inhibitors and Memantine have 
also shown benefit in clinical trials on VaD patients, yet their efficacy and 
significance of clinical improvement remain controversial. Cholinergic deficits 
are observed in VaD(Mesulam et al., 2003), thus traditional ChEIs have been 
tested in various clinical trials. However, ChEIs were unable to produce 
significantly beneficial and disease-modifying improvement in VaD 
patients(Kavirajan and Schneider, 2007). A few studies have also examined the 
efficacy of Memantine in VaD patients, showing good tolerance but limited 
improvement of cognitive function, although the efficacy of the medication may 
depend on specific vascular deficits as well as certain level of disease 
severity(Wilcock, 2003).  
A number of trials have also tested ChEIs and Memantine in mixed dementia 
patients. Patient responses are varied and there has been insufficient evidence to 
support the widespread application of the medications, though some results 
showed comparable treatment effect in mixed dementia patients with AD 
patients(Langa KM et al., 2004). 
Apart from traditional AD medications targeting cholinergic and gluatamatergic 
neurotransmitter systems, the potential utilities of other neurotransmitter receptors 
(e.g. histaminergic and cannabinoid receptors) as therapeutic targets for VaD 

























Chapter 3  
Lewy Body Dementia 
3.1 Lewy bodies and Lewy body dementia 
3.1.1 Definition of Lewy body dementia 
Parkinson’s disease (PD) is clinically characterized by motor symptoms including 
bradykinesia, tremor and rigidity. It has been reported that among PD paients, 
about 30% eventually develop dementia and many exhibit mixed pathology of 
both AD and PD(Mrak and Griffin, 2007). In other cases, dementia symptoms 
may also occur simultaneously with or earlier than symptoms of 
parkinsonism(Aarsland et al., 2009). Dementia symptoms of these patients are 
strongly correlated with abnormal intracellular depositions of Lewy bodies in the 
cerebral cortex(Mattila et al., 2000)(Zarranz et al., 2004). The term ‘Lewy body 
dementia’ is used to classify dementia with overlapping symptoms of PD and AD 
(such as disrupted motor functions of PD and cognitive deficit of AD), but is 
specifically featured by the neuropathological hallmark of Lewy body deposits in 








3.1.2 Lewy bodies 
 




Lewy bodies (LBs) are named after Frederick H. Lewy who first recognized and 
described the particles in the nucleus basalis of Meynert and the dorsal vagal 
nucleus of Parkinson’s disease patients in the early 1900s. With the shape and 
structure of intraneuronal eosinophilic spherical inclusions, LBs are composed 
primarily of abnormally processed and aggregated α-synuclein(Trojanowski and 
Lee, 1998). 
Two major types of LBs have been characterized according to morphology and 
location: 1) classical LBs, primarily found in the brainstem, have a dense central 
core and a spherical ‘halo’; 2) cortical LBs, mostly localized in the neocortex, 
have less well defined shapes without structures like core or ‘halo’.  
3.1.3 Molecular mechanisms of Lewy body dementia 
α-synuclein is a type of synuclein protein abundantly expressed in the brain, 
mostly at presynaptic terminals. α-synuclein plays a regulatory role in many 
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neurodegenerative events by interacting with proteins and lipids. α-synuclein 
promotes the polymerization of microtubules and regulates the phosphorylation of 
tau proteins which are involved in the maintenance of cytoskeleton 
stability(Jensen et al., 1999). α-synuclein is able to inhibit the uptake of dopamine, 
and the excessive amount of dopamine increases susceptibility of dopaminergic 
neurons and induces subsequent cell apoptosis (Wersinger and Sidhu, 2003)(Lee 
et al., 2001). α-synuclein has also been related to mitochondria damage(Müller et 
al., 2013), possibly due to its role in suppressing histone acetylation(Kontopoulos 
et al., 2006). α-synuclein induced impairment of metal homeostasis has also been 
reported(Wright et al., 2009). 
LBs are considered to be histological hallmarks of Parkinson’s disease, however 
they have also been identified in other neurodegenerative diseases, such as 
Alzheimer’s disease patients(Derouesné, 1993), rendering the differentiation of 
AD from LBD more difficult. 
 
3.2 Clinical Features of Lewy body dementia 
LBD patients share similar clinical symptoms with other types of 
neurodegenerative disorders, including cognitive dysfunction, memory 
impairment, neuropsychiatric disorders (depression, delusion and hallucination), 
as well as Parkinsonism, which makes the accurate diagnosis of LBD difficult. 
Without well characterized and accepted diagnostic criteria, LBD patients are 
often misdiagnosed to have Alzheimer’s disease, multi-infarct dementia, 
Parkinson’s disease, or vascular dementia.  
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Moreover, identification of different LBD subtypes has also been challenging. 
There are two common subtypes of LBD: Parkinson’s Disease Dementia (PDD) 
and Dementia with Lewy Bodies (DLB). Generally, patients with PDD/DLB 
develop similar features in multiple aspects:  
 
1) similar clinical symptoms of Parkinsonism, fluctuating cognition, less severe 
memory deficits but more pronounced problems in attention and executive 
functions compared to AD(Ballard et al., 2002), visual hallucinations, and REM-
sleep behavior disturbance; 
2) pathological evidence of senile plaques and neurofibrillary tangles, relatively 
mild loss of neurons and synapses compared to AD, and most importantly high 
density of cortical Lewy bodies(Schulz-Schaeffer, 2010);  
3) frequent occurrence of neuropsychiatric symptoms (Aarsland et al., 
2007)(Klatka et al., 1996) ; worse severity of certain symptoms compared to AD, 
such as apathy, depression and visual hallucinations. It has been suggested that 
relatively worse condition of neuropsychiatric symptoms could become one 
specific criterion to differentiate LBDs from AD, and serve as a potential 
therapeutic target for LBDs.  
4) similar neurochemical alterations, such as cholinergic deficits(Aarsland et al., 
2009). Extensive loss of cholinergic markers is existent in LBD patient brains, 
including ChAT activity reduction(Tiraboschi et al., 2002) and loss of cholinergic 
neurons, while postsynaptic muscarinic receptors remain relatively intact or are 
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even up-regulated in certain brain regions. Cholinergic markers in LBDs have 
been linked with not only cognitive deficits(Tiraboschi et al., 2002), but also with 
neuropsychiatric symptoms(Ballard et al., 2000), which could explain the 
beneficial effect of ChEIs on cognitive functions and psychiatric symptoms in 
PDD and DLB(Aarsland et al., 2004). Although ChEIs seem to exhibit good 
potency in treating LBD patients, as they show even better response to 
cholinesterase inhibitors than AD patients, ChEIs may increase the chance of 
developing side effects of vomiting, nausea and tremor(Emre et al., 2004). 
Limited efficacy of ChEIs in improving cognition and psychiatric parameters of 
LBD patients has also been reported(Dubois et al., 2012).  
Despite many shared features, PDD and DLB still exhibit differences in their 
clinical presentations. Although PDD and DLB patients have combined dementia 
and Parkinsonism pathology, the time sequence of symptomatic appearance of the 
two pathologies can be different, which has become one clinical diagnostic 
standard to differentiate PDD and DLB: for PDD patients, dementia symptoms 
develop at least one year after the appearance of Parkinsonism, whereas for DLB, 
dementia occurs before, simultaneously with, or within one year of the onset of 
Parkinsonism(McKeith et al., 2005).  
3.3 Clinical effects of ChEIs and Memantine in LBDs 
As previously described, both PDD and DLB have cholinergic deficits(Aarsland 
et al., 2009), which led to clinical trials of ChEIs in LBD patients. Some studies 
suggest that LBD patients respond to ChEIs better than AD patients and show 
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improvement of cognition, global outcome as well as psychiatric symptoms 
(Ballard et al., 2000)(Aarsland et al., 2004). However, limited efficacy in 
improving cognitive outcomes and psychiatric factors(Dubois et al., 2012) as well 
as significantly up-regulated side effects like vomiting, nausea and tremor(Emre 
et al., 2004) have also been reported.  
Neurochemical characterization of the glutamatergic system has also been carried 
out in LBD cohorts, reporting reduced expression and impaired downstream 
signaling of glutamate receptors(Thorns et al., 1997)(Albasanz et al., 2005). The 
NMDA receptor blocker Memantine has been tested in a few small trials reporting 
conflicting results(Ridha et al., 2005)(Sabbagh et al., 2005)(Emre et al., 
2010)(Mathys et al., 2013)(Takaya et al., 2013).  
The potential utilities of other neurotransmitter receptors (e.g. histaminergic and 































 Chapter 4 
The Cannabinoid System in the Central Nervous System 
4.1 General description 
 
Illustration 4.1: Cannabinoid ligands and neuronal cannabinoid system 
(Picture source: http://www.nature.com/nrc/journal/v3/n10/images/nrc1188-i1.jpg) 
 
Cannabis sativa has been widely used in many countries for thousands of years, 
but it was not until the mid-20
th
 century that researchers began to discover and 
characterize the neurochemical functions of endogenous cannabinoid system, as 





4.1.1 Cannabinoid receptors 
Before the identification of cannabinoid receptors in the 1980s, cannabinoids 
were considered to directly interact with cell membrane and exert physiological 
effects. The discovery of cannabinoid receptors greatly enhanced the 
understanding of cannabinoid mechanism, which is similar to other 
neurotransmitter systems: ligands or stimulants bind onto synaptic receptors and 
trigger downstream signaling transduction. Two major subtypes of cannabinoid 
receptors, CB1R and CB2R, have been characterized. Since the 1990s, radioligand 
autoradiography and in situ hybridization histochemistry were able to localize the 
wide distribution and great abundance of Cannabinoid CB1 receptors and mRNA 
in human brain areas of basal ganglia, cerebellum and cerebral cortex, indicating 
the potential involvement of cannabinoid receptors in memory, cognition and 
motor functions (Glass et al., 1997)(Westlake et al., 1994).  
Activation of Gi/o protein coupled Cannabinoid CB1 receptors inhibits adenylyl 
cyclase and decreases the production of cAMP, although stimulation of cAMP has 
also been observed(Maneuf and Brotchie, 1997)(Glass and Felder, 1997), possibly 
through Gs protein mediated effect. 
CB2 receptors have relatively confined expression in peripheral immune-related 
tissues and organs (Lynn and Herkenham, 1994). Due to lack of specific 
antibodies and limitation of techniques, many earlier reports claimed the absence 
of CB2 receptors in the brain. Nowadays, whether  brain CB2 receptors can be 
functionally active under normal physiological conditions remains 
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controversial(Chin et al., 2008)(Van Sickle et al., 2005)(Viscomi et al., 2009), but 
accumulating results have indicated that, in conditions of chronic 
neuroinflammation or neurodegenerative disorders, CB2 receptors can be widely 
expressed in microglia cells, astrocytes and neural progenitor cells(Palazuelos et 
al., 2006)(Benito et al., 2003). This may represent a protective response to brain 
injury and neurotoxicity, as activation of CB2 receptors in glia cells can suppress 
the release of pro-inflammatory molecules (IL-1, TNFα, NO, IL-6), and promote 
the production of anti-inflammatory molecules (IL-4, IL-10). 
Some other receptors also respond to cannabinoid ligands, such as 
GPR55(Brusberg et al., 2009), GPR18(Marchalant et al., 2009) and TRPV-1 
receptors(Campos and Guimarães, 2009), which contribute to cannabinoid 
modulation of neuropathic pain, cell migration and proliferation, mood processing, 
neuroinflammation and other physiological functions.  
4.1.2 Cannabinoid ligands 
Cannabinoid compounds are divided into three major groups: the 
endocannabinoids that are naturally synthesized in human body such as 
Anandamide and 2-AG; the phytocannabinoids extracted from Cannabis and 
other related plants, such as Δ9‐THC; the synthetic cannabinoids produced under 
chemical synthesis and structural modification with cannabinoid receptor-
agonizing properties, such as ACEA and ACPA.  
Two major endocannabinoids, anandamide and 2-AG, are derived from integral 
components of cellular membrane lipid layers, only synthesized and released 
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upon membrane depolarization and other stimulations. Anandamide (AEA) was 
the first identified endogenous cannabinoid receptor ligand(Devane et al., 1992), 
with higher affinity for CB1 receptor than CB2. Upon membrane depolarization 
and subsequent increase of intracellular calcium, AEA is produced from its 
phospholipid precursor N-arachidonoyl phosphatidyl ethanolamine(Di Marzo et 
al., 1994), activates Gi/o protein coupled cannabinoid receptors and regulates 
many downstream signaling pathways, including inhibition of adenylyl cyclase 
and activation of MAPK pathways. 2-Arachidonoylglycerol (2-AG) is also an 
endogenous CB1 receptor agonist, synthesized from arachidonic acid-containing 
diacylglycerol (DAG). Downstream signaling of AEA and 2-AG can be 
terminated by carrier-mediated uptake and intracellular hydrolysis by membrane-
bound fatty acid amide hydrolase (FAAH, primarily degrades AEA) and 
Monoacylglycerol lipase (MAGL, mainly responsible for hydrolyzing 2-AG).  
Phytocannabinoids are usually hydrophobic but soluble in lipids or other non-
polar organic solvents. Many phytocannabinoids have been studied, among which 
Δ9‐tetrahydrocannabinol (THC) is the major psychoactive component isolated 
from the plant Cannabis. Cannabidiol is another important component of 
Cannabis, but unlike Δ9‐THC, it is non-psychotic and has relatively low affinity 
for both CB1 and CB2 receptors.  
Since the discovery of endocannabinoids, researchers have been modifying their 
chemical structures to improve their solubility and receptor binding selectivity, as 
well as reduce psychoactive properties. Many cannabinoid agonists as well as 
selective cannabinoid receptor antagonists/inverse agonists with higher receptor 
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specificity have been synthesized and studied for their potential pharmacological 
and therapeutic effects. 
4.1.3 Cannabinoid CB1 receptor: retrograde modulation of 
neurotransmission 
The endogenous cannabinoid system modulates neurotransmission in a retrograde 
pattern(Velasco et al., 2012). Upon the release of neurotransmitters into synaptic 
cleft and binding with postsynaptic receptors, the synthesis of endogenous 
cannabinoid compounds from their membrane-bound lipid precursors is triggered, 
while at the same time up-regulating intracellular calcium level. 
Endocannabinoids are then released into the synaptic cleft and activate 
presynaptic Cannabinoid CB1 receptors as a retrograde messenger. Activated CB1 
receptors at the presynaptic terminal trigger Gi/o protein related effects, decrease 
voltage-gated Ca
2+
 channel conductance and reduce calcium current 
amplitude(Henry and Chavkin, 1995), and activate inwardly rectifying K+ 
channels(Henry and Chavkin, 1995). Subsequent down-regulation of presynaptic 
calcium level restrains the docking and fusion of synaptic vesicles and the release 
of neurotransmitter molecules. In this way cannabinoid receptors modulate the 







4.2 Status of cannabinoid receptors in Alzheimer’s disease 
Earlier studies on the neurochemical characterizations of post-mortem AD brains 
have reported abnormal status of cannabinoid receptors, including reduced CB1 
receptor expression in hippocampus (37-45%), caudate (49%), substantia nigra 
and globus pallidus (20-24%) of AD brains, along with impaired coupling to G 
proteins and increased receptor nitration(Ramirez et al., 2005). Reduced CB1 
receptor binding with ligands was also observed in these brain regions compared 
to controls. A previous study from our lab using post-mortem human brain 
suggested the intact status of CB1 receptors in multiple areas of post-mortem 
human AD brain (frontal cortex, caudate, anterior cingulate cortex, hippocampus), 
while patients with higher frontal CB1 density scored better in pre-death cognition 
tests, indicating a positive correlation between CB1 and cognitive functions(Lee et 
al., 2010). 
Immunohistochemical staining assay has also been applied to examine the level of 
cannabinoid receptors around senile plaques. While the density of CB1 receptors 
was unchanged in the vicinity of plaques in the hippocampus and entorhinal 
cortex of postmortem AD patient brains, increased expression of CB2 receptors 
and FAAH were observed in neuritic plaque-related astrocytes and 
microglias(Benito et al., 2008). Up-regulation of FAAH in plaques is correlated 
with reactive gliosis around Aβ depositions, possibly due to increased production 




4.3 Neuroprotective roles of cannabinoids 
4.3.1 Against amyloid pathology 
Cannabinoids exhibit multiple roles of neuroprotection against the detrimental 
effects of Aβ pathology, including stimulating neurogenesis, producing 
neurotrophins, suppressing oxidative stress, inflammation and neurotoxicity. 
Inhibiting AChE:  While mainly being targeted to enhance cholinergic 
neurotransmission in AD treatment, the cholinergic metabolizing enzyme 
acetylcholinesterase (AChE) has also been investigated for its role in binding with 
Aβ and accelerating amyloid fibrils formation(Inestrosa et al., 1996). According 
to Eubanks et al., the cannibinoid THC turned out to be a more powerful AChE 
inhibitor than most AChEIs, and may provide dual action against Aβ pathology 
by not only increasing cholinergic neurotransmission but also suppressing Aβ 
aggregation(Eubanks et al., 2006).   
Modulating neuroprotective molecular pathways: Anadamide and noladin-
etherwere found to inhibit β-amyloid toxicity through a MAPK-dependent 
pathway, suggesting that a CB activating MAPK pathway might prevent Aβ-
induced neurodegeneration(Milton, 2002)(Haghani et al., 2012b). Other reported 
mechanisms include rescuing or enhancement of PPAR-γ(Fakhfouri et al., 2012) 
and Wnt/ β-catenin signaling pathway (Esposito et al., 2006a). 
Suppressing neuroinflammation: Aβ has been reported to elevate endogenous 
cannabinoid palmitoylethanolamide (PEA) level, which then exerts protection 
against Aβ-induced pro-inflammatory molecules and counteract Aβ-induced 
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astrogliosis(Harvey et al., 2012). Cannabidiol (CBD), the main non-psychotropic 
component of cannabis, exerts its anti-inflammatory effect against Aβ by 
inhibiting reactive gliosis and pro-inflammatory molecules such as NO and IL-
1β(Esposito et al., 2005)(Esposito et al., 2006b)(Esposito et al., 2009). 
Defending against Aβ-induced neurotoxicity and oxidative stress: CB1 selective 
agonist ACEA is reported to be neuroprotective against Aβ induced 
electrophysiological alterations and neurotoxicity in pyramidal neurons, by 
increasing neuronal firing frequency and suppressing abnormal neuronal 
excitability(Haghani et al., 2012a).In another study using PC12 and SHSY5Y cell 
lines, anandamide attenuated Aβ induced neurotoxicity and cell death in a CB1/2 
receptor-unrelated pathway(Harvey et al., 2012).  
4.3.2 Against ischemia 
Cannabinoids also protect against ischemia. Exogenous cannabinoid agonist WIN 
55212-2 was found to reduce neuron loss and decrease infarct volume after global 
and focal cerebral ischemia through CB1 receptor-related effect, though similar 
protective effect on cultured neurons from in vitro hypoxia and glucose 
deprivation was insensitive to CB1 or CB1 antagonists(Nagayama et al., 1999). On 
the other hand, the endogenous 2-AG level is significantly up-regulated under 
conditions of head injury in a mouse model, while administration of synthetic 2-
AG attenuated damages induced by acute trauma through a CB1-dependent 




4.3.3 Against neurotoxicity 
The non-psychoactive synthetic cannabinoid agonist HU-211 protects rat brain 
primary culture neurons and cortical neuronal cultures from NMDA or 
excitotoxins induced neurotoxicity by blocking the NMDA channel(Eshhar et al., 
1993).  WIN55212-2, AEA and CP55,940 inhibited calcium current through 
blocking presynaptic N- and P/Q-type calcium channels in cultured rat 
hippocampal neurons(Twitchell et al., 1997). WIN 55212-2 also suppressed 
glutamate release from hippocampal synaptosomes, through similar inhibition on 
N- and P/Q-type calcium channel activity which led to a lower Ca
2+
 influx(Su-
Jane, 2003).  
The protective role of WIN 55,212-2, CP 55,940 and other cannabinoids against 
high NMDA induced neurotoxicity is suggested to be related to cAMP/PKA 
pathway inhibition and subsequent reduction of intracellular calcium 
concentration(Zhuang et al., 2005).  Both CB1 receptor genetic knockout and CB1 
antagonist were able to increase the susceptibility of organotypic hippocampal 
slice cultures to Kainic acid-induced excitotoxicity and massive cell apoptosis, 
which could be rescued by exogenous BDNF treatment, suggesting increased 
production of BDNF as a potential mechanism for CB1 receptor-mediated 
protection against excitotoxicity(Khaspekov et al., 2004).  
4.3.4 Promoting neurotrophic factor production and neurogenesis 
The CB1 agonist 2-AG was found to stimulate FGF-mediated axonal growth, 
while CB1 antagonists inhibited axonal growth(Williams et al., 2003). The 
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Marchalant lab reported that the activation of cannabinoid receptors by 
WIN55212-2 can promote neurogenesis, while its antagonism of TRPV-1 
receptors is likely to suppress neuroinflammation in microglia cells(Marchalant et 
al., 2009).
 
CB2-selective agonists were able to stimulate neural progenitor cell proliferation 
both in vivo and in vitro. On the other hand, CB2-deficient cells and mouse model 
showed impairment in neural progenitor cell proliferation(Palazuelos et al., 2006). 
Activation of CB2 receptors has been related to stimulation of PI3K, Akt and JNK, 
which contributes to the pro-survival effects(Viscomi et al., 2009). 
Indirect enhancement of cannabinoid tone seems to be beneficial as well. FAAH 
inhibitors increase the level of endocannabinoids and enhance memory 
acquisition in rat models through activation of PPAR-α receptors(Mazzola et al., 
2009). Application of cannabinoid uptake inhibitor at an early stage significantly 
up-regulated endocannabinoid levels in rodents, reversingAβ-induced brain 
damage and memory loss. Yet the administration of FAAH inhibitor VDM-11 in 
later stage worsens memory retention, suggesting early enhancement of 
endocannabinoid level as a potential neuroprotective intervention against AD 
pathology(Stelt et al., 2006).  
Cannabinoid agonists rescued rat hippocampal neurons from postsynaptic density 
protein loss through mediating presynaptic calcium channels, though this effect 
was attenuated after desensitization by long-term exposure to WIN 55212-2(Kim 




4.3.5 Against BPSD 
CB1 receptors are abundantly expressed in many brain areas related to cognition 
and mood regulation such as hippocampus, hypothalamus, amygdala, prefrontal 
cortex(Herkenham et al., 1990). A number of studies have established the role of 
CB1 receptors in modulating depression and anxiety-related behavioral and mood 
disorders. Decreased endocannabinoid neurotransmission as well as reduced 
levels of CB1 receptors have been observed in both animal models of depression 
or stress, and in depressed human cases(Parolaro et al., 2010). CB1 knockout or 
pharmacological blocked rodent animals showed more passive and anhedonic 
response under stress(Martin et al., 2002)(Steiner et al., 2007), lower level of 
motor activity and enhanced anxiety-like or depressive movements  in behavioral 
tests(Mato et al., 2007). On the other hand, direct or indirect CB1 enhancing 
interventions in animal models(Kathuria et al., 2003)(Macr   and Laviola, 
2004)(Aso et al., 2012)(Hill and Gorzalka, 2005)(Gobbi, 2005)  (including 
application of CB1 agonists, endocannabinoid re-uptake inhibitors and FAAH 
inhibitors) showed anti-depressant properties by reducing immobility, promoting 
active struggling movements, elevating appetite, increased sociability, etc.  
Injection of cannabinoid antagonists in rat and mouse models has been reported to 
induce anxiety-enhancing effect(Dono and Currie, 2012) and anxiogenic-like 
behavior in a mouse model(Zarrindast et al., 2010). On the other hand, anxiolytic 
and panicolytic responses have been observed in various animal studies in which 
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injection of cannabinoids or FAAH inhibitor were applied, such as 
ACEA(Casarotto et al., 2012), AEA analog Methanandamide, or FAAH inhibitor 
URB597 (Rubino et al., 2008b), WIN 55,212-2(Campos and Guimarães, 
2009)(Zarrindast et al., 2010), and THC(Rubino et al., 2008a).  
The CB1 antagonist SR141716A, also known as Rimonabant, has been widely 
studied for its potential effect against obesity, tobacco dependence, cardiovascular 
events and metabolic disorders. However, severe adverse psychiatric side effects 
have been observed in a number of human clinical trials of Rimonabant, showing 
increased rates of depression, anxiety, stress and insomnia , more cases of 
attempted or committed suicide compared to the placebo group(Després et al., 
2005)(Topol et al., 14)(Motaghedi et al., 2011)(Gruber et al., 1996), leading to its 
premature discontinuation. 
Unlike Rimonabant, THC is known as the major psychotropic components of 
cannabis and is probably responsible for mood-lifting, stress-reducing and 
euphoria effects caused by cannabis smoking, although its anxiogenic property 
has also been reported under higher doses and acute administration. A review 
reported 5 cases in which the usage of marijuana directly decreased symptoms of 
depression (Gruber et al., 1996). Moderate consumption of cannabis has also been 
found in clinical trials to ameliorate depressed mood and produce active effects 
(Denson and Earleywine, 2006). 
The mechanisms underlying the antidepressant effect of cannabinoids are similar 
to those of other anti-depression drugs: they increase the level of monoamines 
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(serotonin, noradrenaline) by inhibiting MAO, reduce synaptic re-uptake, or 
directly enhance the firing ability of neurons producing these neurotransmitters 
(For review see(Gorzalka and Hill, 2011)).  Cannabinoids are also reported to 
modulate the homeostasis of the hypothalamic-pituitary-adrenal (HPA) axis by 
suppressing its hyperactivity and restraining the secretion of stress-induced 
glucocorticoids(Barna et al., 2004)(Patel et al., 2004)(Steiner et al., 2008). 
While cannabinoids exhibit ameliorating effects in animals and patients under 
conditions of stress, depressed mood or anxiety, they may induce unwanted 
psychiatric problems in healthy populations. The connection between cannabis 
consumption and psychotic symptoms has long been recognized. Cannabis-
induced psychotic symptoms, including hallucinations and delusions, are usually 
acute, transient, and related to consumer’s age, exposed dose and previous history 
of psychotic problems (D’Souza et al., 2009).  
 
4.4 Cannabinoid antagonists 
4.4.1 Memory enhancing effect 
CB1 receptors are highly expressed in many CNS regions such as the 
hippocampus and cortex that are crucial in higher brain functions, and the roles of 
CB1 agonists and antagonists on regulating cognition and memory have been 
widely studied. Various natural cannabinoids and synthetic CB1 agonists have 
been shown to impair animal performance of attention, spatial and non-spatial 
learning, short-term memory, recognition memory, social behaviors and so 
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on(Mallet and Beninger, 1998). On the other hand, blocking Cannabinoid CB1 
receptors seems to enhance memory function and alleviate amnesia deficits in 
behavioral test studies of animal models. CB1R selective antagonists/inverse 
agonists (SR141716A, AM281 etc.) have shown to 1) ameliorate memory deficits 
induced by cannabinoids(Mallet and Beninger, 1998)(Terranova et al., 1996), 2) 
reduce passive avoidance behavior and impaired memory retention by injection of 
β-amyloid peptides(Mazzola et al., 2003), 3) restore cognitive impairments 
induced by a muscarinic antagonist(Rabbani et al., 2012)(Takahashi et al., 2005). 
In certain studies, CB1 inverse agonists were able to attenuate muscarinic 
antagonist-induced cognitive impairment in animal models. Co-administration of 
CB1 antagonist Rimonabant with acetylcholinesterase inhibitor Donepezil showed 
synergistic memory enhancement effect in rat radial-arm maze experiment(Wise 
et al., 2007).  Different combinations of cannabinoid antagonists/inverse agonists 
and muscarinic antagonists have been tested in animal models of memory and 
cognition: CB1 antagonist/inverse agonist SLV330 reduced Muscarinic 
M1/M3receptor antagonist scopolamine-induced memory deficits, while showing 
synergistic memory enhancing effect in mice T-maze Continuous Alternation 
Task model(de Bruin et al., 2010); addition of AM281 significantly reduced 
exploration time in mice Novel Object Recognition (NOR) model while mice 
treated with scopolamine alone spent significantly longer time than 
control(Rabbani et al., 2012); a novel CB1 inverse agonist MK-7128 improved 
scopolamine-induced deficits in spontaneous alternation performance and object 
recognition ability in both Y-maze spontaneous alternation task and object 
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habituation task of mouse model. CB1 antagonist Rimonabant (SR141716A) co-
administration reversed scopolamine-induced memory impairment in the elevated 
T-maze memory model(Takahashi et al., 2005), while co-administration of 
SR141716A with acetylcholinesterase inhibitor Donepezil showed synergistic 
memory enhancement effect in rat radial-arm maze experiment(Wise et al., 2007), 
since Donepezil is well known known to ameliorate memory deficit as a 
traditional dementia treatment. Meanwhile, novel chemical compounds with dual 
pharmacological actions of both acetylcholinesterase inhibition and Cannabinoid 
CB1 antagonism have been designed and synthesized(Lange et al., 2010). Hence, 
CB1 antagonists/inverse agonists are considered potential therapeutic drugs 
against cognitive decline and memory impairment in neurodegenerative diseases, 
with underlying mechanisms of up-regulating acetylcholine release(Degroot et al., 
2006). 
4.4.2 Against obesity, hyperphagia and cerebrovascular events 
CB1 antagonists/inverse agonists such as Rimonabant have been studied for their 
therapeutic potential for treating obesity and metabolism disorder. Up-regulated 
expression and increased activity of both central and peripheral CB1 receptors are 
correlated with hyperphagia and weight gain, thus much effort has been devoted 
into the synthesis and testing of CB1R-selective blockers in animal models and 
clinical trials for their appetite-controlling and anti-obesity effects. For example, 
CB1 selective antagonist and inverse agonists SR141716A, or Rimonabant, was 
initially found to suppress appetite, decrease food intake as well as reduce 
weight(Colombo et al., 1998). With the accumulation of trials, CB1 antagonists 
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also exhibited certain beneficial properties against cerebrovascular events. 
Rimonabant has been tested in large-scale clinical trials for its efficacy in treating 
obesity and metabolic disorders as well as cerebrovascular events, although it was 
suggested by further investigations to cause serious psychiatric side effects such 
as depression and suicidal intentions(Topol et al., 14), which led to 
discontinuation of clinical trials.  
4.4.3 Pharmacological mechanisms of Cannabinoid CB1 antagonists/inverse 
agonists 
The mechanism of CB1 inverse agonists inhibiting food intake and enhancing 
memory might be related to their “inverse cannabimimetic” effects(Pertwee, 
2005). SR141617A and its structurally similar CB1 inverse agonists such as 
AM281, AM251 and LY320,135 inhibit [
35S]GTPγS binding to neuronal cells. 
There have been a number of studies suggesting that cannabinoid inverse agonists 
increase the likelihood of not only CB1 receptors but also other Gi/o-protein 
coupled receptors being bound to inactive G-protein (attached with GDP) or 
getting uncoupled from G-protein, rather than bound to active G-protein (attached 
with GTP)(Vasquez and Lewis, 1999)(Pertwee, 2005). Also, in addition to 
interacting with the binding sites of cannabinoid agonists and producing a 
competitive antagonism effect, these inverse agonists may also bind to another 
site on the CB1 receptor in an allosteric manner and produce inverse 
agonism(Sim-Selley et al., 2001). Inverse agonism of CB1 receptors increase 
neuronal calcium currents and abolish the inhibitory effect of the 
endocannabinoid system on neurotransmitter release (ACh, glutamate, GABA, 
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noradrenaline, dopamine etc.), and these responses have been related to decreased 
appetite and enhanced memory function. 
Instead of the inverse agonist Rimonabant, some neutral CB1 antagonists without 
the inverse effect of agonists have been developed and confirmed to have efficacy 
in modulating obesity and metabolic disorders, without inducing severe 
psychiatric side-effects. For example, CB1 neutral antagonist NESS0327 was able 
to suppress appetite and food intake without inducing psychiatric side-effects such 
as anxiety and loss of motivation for reward. The underlying mechanism probably 
does not involve interfering with endocannabinoid signaling, more likely related 
to NESS0327 not suppressing the constitutive activity of CB1 receptors regulating 
GABAergic and glutamatergic neurotransmission in mesocorticolimbic area 
which is important for modulating anxiety and depression(Meye et al., 2012). 
Some other studies on CB1 neutral antagonists such as LH-21 and AM6545 
suggest that their reduced psychiatric side effects  might be related to their 
relatively confined effects in the peripheral system and lower ability to penetrate 




























Chapter 5  
Histaminergic H3 receptors in the Central Nervous System 
5.1 Overview of histaminergic system and H3 receptors 
5.1.1 CNS histaminergic system 
 
Illustration 5.1: Projection of histaminergic neurons in the brain 
(Picture source: http://www.nature.com/nrn/journal/v4/n2/images/nrn1034-f1.jpg) 
 
Histamine is an important excitatory neurotransmitter. CNS histaminergic 
neurons are located exclusively in the tuberomamillary nucleus of the posterior 
hypothalamus and have a widespread projection throughout the CNS, including 
areas of cerebral cortex, hippocampus, striatum, thalamus and 
hypothalamus(Esbenshade et al., 2008). The neurotransmitter histamine is known 
to interact with four subtypes of G-protein coupled histaminergic receptors, H1-
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H4(Brown et al., 2001). Histaminergic H1, H2 and H4 receptors have been well 
studied as important drug targets against peripheral inflammatory and allergic 
conditions, such as ulcer(Ruoff et al., 1979), asthma(Eiser et al., 1981) and 
arthritis(Tanaka et al., 1997). 
5.1.2 Histaminergic H3 receptors 
Histaminergic H3 receptors were originally characterized to serve as presynaptic 
inhibitory autoreceptors to control the release of histamine when they are 
activated on the somata, axons and dendrites of histaminergic neurons(Arrang et 
al., 1983). With the accumulation of further studies, H3 receptors are found to also 
localize on other types of neurons and can work as presynaptic heteroreceptors 
inhibiting the synthesis and release of multiple neurotransmitters that are crucial 
to cognitive functioning(Haas et al., 2008). Conversely, abundant studies using 
both in vitro and in vivo models have supported the role of histaminergic 
antagonists/inverse agonists on up-regulating release of these important 
neurotransmitters, including acetylcholine(Clapham and Kilpatrick, 1992), 
dopamine(Munzar et al., 2004), norepinephrine(Medhurst et al., 2007), 
serotonin(Schlicker et al., 1988) and noradrenaline(Schlicker et al., 1989). 
The molecular signaling pathways modulated by H3 receptors have also been 
characterized. H3 receptors belong to the family of Gi/o -protein coupled receptors, 
and their inhibitory effect on neurotransmitter synthesis has been related to 
suppressed adenylate cyclase(Lovenberg et al., 1999), PKA and CaMKII 
pathways(Vohora and Bhowmik, 2012). Other downstream transduction pathways 
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of H3 receptors include activation of MAPK(Drutel et al., 2001), phospholipase 
A2(Morisset et al., 2000), Akt(Mariottini et al., 2009) and GSK3β (Bongers et al., 
2007). 
 
5.2 Potential roles of Histaminergic H3 receptors in treating 
neurodegenerative diseases 
The multi-functional neuromodulatory ability of histamine H3 receptor has 
attracted much attention for treating CNS diseases because of its potential to 
modulate multiple target systems. Because of their pharmacological enhancement 
on the release of multiple neurotransmitters, various H3 antagonists/inverse 
agonists have been tested in animal models and also in clinical trials for the 
treatment of cognitive impairments in neurodegenerative diseases, including AD, 
PD, ADHD, with effects like improving cognitive and learning 
performances(Miyazaki et al., 1997)(Medhurst et al., 2007), enhancing memory 
retrieval(Pascoli et al., 2009), and activating disease-modifying signaling 
pathways and neurotransmitter release(Bitner et al., February)(Nowak et al., 
2008). The Histaminergic H3 receptor antagonist Thioperamide has been found to 
facilitate short-term memory, spatial memory as well as memory retention by 
injection into the nucleus accumbens and nucleus basalis as well as i.p. injection 
in animal models(Kraus et al., 2013)(Orsetti et al., 2002)(Orsetti et al., 2001). Co-
administration of nicotine with H3 antagonist ABT-239 further enhanced nicotine-
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induced augmentation of memory formation and consolidation ability in the 
mouse elevated plus-maze test(Kruk et al., 2012). 
With abundant expression in brain areas related to cognition, such as 
hippocampus, caudate, putamen, frontal cortex, but low level in peripheral organs 
such as heart, lung, liver(Brioni et al., 2011), histamine H3 receptors are 
considered to be a potential CNS target with low peripheral side effects.    
 
5.3 Status of Histaminergic H3 receptors in dementia 
Disease-modifying properties of Histaminergic H3 receptor antagonists have been 
studied at molecular level as well in AD animal models, with multiple reports of 
their role of enhancing GSK-3β phosphorylation and up-regulating cortical CREB 
(cAMP response element binding protein)(Bitner et al., 2011)(Brioni et al., 2011). 
These neurochemical alterations by H3 antagonists have been related to cognitive 
improvement and attenuated tau pathology. 
As a potential therapeutic target, the status of Histaminergic H3 receptors has been 
clinically investigated in AD patients using radioligand autography(Medhurst et 
al., 2007, p. 189254)(Medhurst et al., 2009). Preservation of H3 receptors has been 
observed in various brain areas including cortex and hippocampus. Even patients 
at late-stage of AD had relatively intact H3 receptors in certain regions(Medhurst 
et al., 2009). Although not significantly different from non-demented control, H3 
receptor binding in the frontal lobe was correlated with AD severity prior to death. 
In other words, patients with higher frontal cortex H3 receptor density presented 
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worse cognitive deficits before death. This result was consistent with the 
inhibitory role of H3 receptor activation on the release of cognition-related 
neurotransmitters.  
The potential role of H3 receptors in other subtypes of dementia, e.g. vascular 





















































Materials and Methods 
6.1 Materials 
6.1.1 Materials for Radioligand Saturation Binding Assay 
6.1.1.1 Assay buffer for brain tissue homogenizing, washing and dilution 
Ice-cold 50 mM Tris–HCl buffer, pH 7.5  
6.1.1.2 BSA solution for creating standard curve in protein concentration assay 
Stock solution: 1.41mg/ml Bovine Serum Albumin in dH2O 
6.1.1.3 Coomasie Blue for protein concentration assay 
Pierce Coomassie Plus Protein Assay Reagent (Thermo Fisher Scientific) 
6.1.1.4 Solution for increasing protein solubility before protein concentration 
assay 
0.5M NaOH 




7- yl)oxy] -N-methyl-3-pyridinecarboxamidehydrochloride, speciﬁc 









6.1.1.6 Chemical as non-radioactive cold blocker 
Thioperamide (Tocris, Cat. No. 0644) 
6.1.1.7 Liquid Scintillation Oil 
Optiphase 'Hisafe' 2 (PerkinElmer, Cat. No. 1200-436) 
6.1.2 Materials for human neuroblastoma cell line maintenance and viability 
test 
6.1.2.1 SH-SY5Y neuroblastoma cell culture medium 
DMEM: Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen Gibco®, Cat. 
No. 11965), with addition of 4.5g/L D-Glucose and 110mg/L sodium pyruvate as 
extra source of energy; L-glutamate as essential amino acid for maintaining 
neuronal function. 
F-12: Ham’s F-12 Nutrient Mix with L-Glutamate (Invitrogen Gibco®, Cat. No. 
11765). 
FBS: Thermo Scientific* HyClone Defined Fetal Bovine Serum. 
NEEA: MEM Non-Essential Amino Acids Solution, 100X (Invitrogen Gibco®, 
Cat. No. 11140), as growth supplement.  
Pen strep: Penicillin-Streptomycin (Invitrogen Gibco®, Cat. No. 15070), a 
mixture of antibiotics against bacterial contamination. Penicillin interferes 
directly with the turnover of the bacteria cell wall and also increases the release of 
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enzymes that further alter the cell wall. Streptomycin binds to the 30S subunit of 
the bacterial ribosome leading to inhibition of protein synthesis. 
Trypsin-EDTA: 1x 0.25% Trypsin-EDTA, Phenol Red(Gibco®, Cat. No. 25200).  
6.1.2.2 MTS cell proliferation assay 
CellTiter 96® AQueous One Solution Cell Proliferation Assay(Promega, Cat. No. 
G3581) 
Containing 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) and phenazine ethosulfate (PES).  
MTS is an insoluble tetrazolium purple dye that can be reduced through accepting 
electrons from metabolic products of viable cells, e.g. NADH or NAPDH. PES 
works as an electron coupling reagent that binds with MTS to form stable solution. 
MTS usually has absorbance of 500~600 nm which can be quantified by a 
spectrophotometer. Reduced MTS turns into a soluble colored formazan product 
with absorbance at around 490nm, showing a visible color change. Dead cells lose 
their ability to reduce MTS and induce a color change. Thus, the percentage of the 
colored formazan product, which can be measured at the wavelength of 490nm by 
a spectrophotometer and compared with controls, is proportional to the percentage 






6.1.3 Materials for Western Blotting assay 
6.1.3.1 Recipes for making buffers and solutions: 
10x PBS solution: For making 5L of 10x PBS (pH=7.4), dissolve NaCl 400g, KCl 
10g, Na2HPO4`(2H2O) 57.6g, KH2PO4(anhydrate) 10g in 5L RO water.  
PBST solution: For making 1L of PBST, dilute 100ml 10x PBS with 900ml RO 
water. Add 1ml Tween20.  
5% BSA or Milk in PBST: For making 100ml 5% BSA/Milk in PBST, dissolve 
5g BSA or non-fat milk powder in 100ml PBST solution.  
10% SDS: For making 100ml of 10% (w/v) SDS (Sodium dodecyl sulfate), 
dissolve 10g SDS in 100ml diH2O. The mixture is vortexed and incubated in 
37 °C water bath to allow full dissolution. 
Running Gel buffer (A) for making SDS-PAGE running gels:  1.5M Tris pH8.8 
(BioRad) 200ml, 10% SDS 9ml and dH2O 400ml 
Stacking Gel buffer (B) for making SDS-PAGE stacking gels: 0.5M Tris (pH=6.8, 
Biorad) 11.5ml, 30% acrylamide 64ml, 10% SDS 3.2ml and dH2O 300ml.  
10% APS: For making 1ml of 10% (w/v) APS (Ammonium persulfate), dissolve 
0.1mg in 1ml diH2O. 





6.1.3.2 Recipes for making SDS-PAGE running Gels 
Table 6.1 Recipes for making SDS-PAGE running Gels: 2 pieces 
 10% 7.5% 
Gel buffer (A) 10ml 15ml 
30% Acrylamide 5ml 5ml 
10% APS 150μl 225μl 
TEMED 12μl 18μl 
 
6.1.3.3 Recipe for making SDS-PAGE stacking Gels 
Table 6.2 Recipes for making SDS-PAGE stacking Gels: 2 pieces 
Gel buffer (B) 5ml 
10% APS 100μl  
TEMED 6μl  
 
6.1.3.4 Laemmli buffer for cell lysis and harvesting 
In Laemmli buffer, 2% SDS induces denaturation and dissociation of proteins, 
which are conferred with negative charge, and subsequently share similar shape 
and final ratio of charge-to molecular weight, so that proteins can be separated by 
the polyacrylamide gels according to molecular size rather than intrinsic electric 
charge. 1.7ml β-Mercaptoethanol is added into each 30ml of 10x Laemmli sample 
buffer (BioRad, Cat. No. 161-0737).  β-Mercaptoethanol reduces disulfide bonds 
in proteins and peptides to allow better separation. 0.01% bromophenol blue is 
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added as a dye to indicate the progression of running. 25% glycerol makes the 
loaded sample dense and stable. 
6.1.3.5 iBlot Dry Blotting system (Invitrogen Life Science Technologies)  
iBlot™ Gel Transfer Device and iBlot™ Gel Transfer Stacks are used for 
Western blotting transferring.  
Each piece of iBlot™ Gel Transfer Stacks, equipped with a copper electrode, can 
serve as an ion reservoir, because its gel matrix is incorporated with either anode 
or cathode buffer.  
iBlot™ Anode Stack, Bottom contains 4 parts, from bottom to top: transparent 
plastic tray, copper electrode layer (anode), bottom transfer gel layer (anode), 
nitrocellulose or PVDF membrane layer.  
iBlot™ Cathode Stack, Top contains 2 parts, from bottom to top: copper electrode 
layer (cathode), top transfer gel layer (cathode). 
During the process of electrophoresis, protein samples processed with Laemmli 
buffer carry negative charges, thus can migrate toward the Anode Stack and be 
transferred onto the membrane. 
6.1.3.6 Materials for Chemiluminescence imaging 
Chemiluminescent HRP (horseradish peroxidase) substrates: 
The Luminata
™
 Western HRP Substrates, including Crescendo and Forte 




Table 6.3 Primary and secondary antibodies 
Primary Antibodies for immunoblots 
Primary Antibodies Species Dilution Supplier 
Anti-Aβ 1-16 (6E10) Mouse 1:1000 Covance 
Anti-phospho-p42/44 
MAPK (ERK1/2) 
Mouse 1:1000 Cell Signaling 
Anti-p42/44 MAPK 
(ERK1/2) 
Rabbit 1:1000 Cell Signaling 
Anti-CB1 Rabbit 1:1000 Sigma 
Anti-M1 Rabbit 1:1000 Millipore 
Anti-M3 Rabbit 1:1000 Millipore 
Anti-β-actin Mouse 1:5000 Sigma 
Secondary Antibodies for immunoblots 
Secondary Antibodies Species Dilution Supplier 
Anti-mouse-HRP Goat 1:5000 Jackson 




6.1.4 Chemicals for cell treatment 
AM251 (Tocris, Cat. No. 1117), Cannabinoid CB1 selective inverse agonist 
AM281 (Tocris, Cat. No. 1115), Cannabinoid CB1 selective inverse agonist 
LY320,135 (Tocris, Cat. No. 2387), Cannabinoid CB1 selective inverse agonist 
PD98059 (Tocris, Cat. No. 1213), MAP kinase kinase inhibitor 
Carbachol, Muscarinic M1 and M3 receptor agonist 
Atropine Sulfate, muscarinic receptor antagonist 














6.2.1 Radioligand Saturation Binding Assay 
6.2.1.1 Theoretical basis 
 
Illustration 6.1: Theoretical basis of radioligand saturation binding assay 
 
A radioligand is a biochemical substance that is radioactively labeled on one 
selected atom (i.e. replacement of specific hydrogen atoms by tritium in 
[
3
H]GSK189254). The labeling of the ligand does not affect its biochemical 
binding properties, but allows its binding with target molecules (i.e. receptors, 
peptides, enzymes) to be measured using radioactivity-sensitive machine and 
reagents.   
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Radioligand saturation binding assay has been widely used to characterize the 
density and binding affinity of receptors in post-mortem tissues. In the assay, 
tissue samples are incubated with multiple concentrations of radioligands, 
which bind with target receptors. At equilibrium, radioactivity can be 
measured with scintillant machine. 
 Theoretically, the incubation time should be sufficient to allow the 
association of radioligand and receptor to reach equilibrium, which means the 
rate of  
Radioligand + Receptor                           Radioligand·Receptor 
(Rate of association, rateon, defined as [Radioligand][Receptor]Kon) 
Equals the rate of 
Radioligand·Receptor                            Radioligand + Receptor 
 (Rate of dissociation, rateoff, defined as [Radioligand·Receptor]Koff).  
At equilibrium, rateon = rateoff. The equilibrium dissociation constant KD is 
then calculated as: 
KD=Koff/Kon = [Radioligand][Receptor]/[Radioligand·Receptor] 
Fractional occupancy is used to represent the fraction of receptors bound to 
radioligand at equilibrium:  
Fractional occupancy = [Radioligand·Receptor]/[Receptor]total 
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= [Radioligand·Receptor]/( [Radioligand·Receptor]+[Receptor]) 
When both the numerator and denominators are multipled by [Radioligand] 
and then divided by [Radioligand·Receptor], 
Fractional occupancy = [Radioligand]/([Radioligand]+ KD) 
When half receptors are occupied, fractional occupancy = 0.5, KD = [radioligand].  
Thus, KD is the concentration of radioligand that can bind with half of the 
receptors upon equilibrium, and is considered a marker of receptor binding 
affinity with the specific radioligand. A small KD indicates high affinity, while a 
large KD suggests low affinity.  
Besides binding with target receptors, radioligand also generates nonspecific 
binding by attaching to nonspecific sites on the tissue sample as well as container 
walls. Although one rule of choosing the appropriate radioligand is to ensure 
maximum specificity to the target receptors, nonspecific binding cannot be totally 
eliminated.  
Total binding = specific binding + nonspecific binding 
In order to calculate the specific binding, a non-radiolabeled selective blocker is 
added to occupy all the target receptors, so that the radioactivity measured is only 
nonspecific binding, which usually exhibits a linear relation with radioligand 
concentration. Total binding is measured using the same amount of proteins and 
concentration of radioligand, but without the presence of a selective blocker. The 
difference between total and nonspecific readings presents specific binding.  
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In saturation binding, the quantity of receptors (Bmax) is fixed, because each unit 
of protein sample is equally divided from the same postmortem tissue sample 
after homogenization, thus each unit carrys the same amount of proteins when 
treated with different concentrations of radioligand. Also, the binding affinity of 
radioligand to the receptor, represented by KD, is considered constant in most 
short-time experimental settings of saturation assay.  
So the level of specific binding can be described as: 
Specific binding 
= Fractional occupancy·Bmax 
= (Bmax·[Radioligand])/([Radioligand]+KD) 
As shown, specific binding is only related to the concentration of free radioligand.  
As only a small portion of radioligand binds, the concentration of free ligand is 
considered identical to the concentration added (Davenport and Russell, 1996).  
By applying multiple concentrations of radioligand onto samples with the same 
amount of proteins and performing a curve-fitting, the constants Bmax and KD can 
then be calculated. 
6.2.1.2 Sample preparation 
For radioligand binding assays, post-mortem brain tissues were thawed on ice and 
dissected free of menings and white matters and subsequently homogenized with 
an Ultra-Turrax homogenizer (IKA, Germany) in ice-cold 50 mM Tris–HCl 
buffer, pH 7.5 at 50 mg tissue wet weight per ml. Homogenates were then 
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centrifuged for 10 min, 4 °C at 20,000 × g, followed by two washes in fresh 
buffer before final centrifugation and storage of tissue pellets at −80 °C.  
6.2.1.3 Liquid scintillation spectrometry 
Before measurement, frozen brain homogenates were thawed, diluted 1:4 with 
assay buffer (ice-cold 50 mM Tris-HCl, pH 7.4) and separated into 2 parts. One 
part is carefully pipetted in triplicates into assay vials containing 6~7 
concentrations (0.05~5 nM) of radioligand, and incubated for 1~2hrs at room 
temperature. The other half is subjected to parallel assays with the addition of 
non-radioactive selective blockers to define non-specific binding. 
Liquid scintillation spectrophotometry was used to measure radioactivity attached 
with receptors with a Wallac 1414  beta-counter at ~45% efficiency. Data output 
in disintegrations per minute (dpm) was obtained from counts per minute (cpm) 
values for each vial after correction for radioactivity quenching. 
Raw dpm data for each sample was entered into EBDA and LIGAND softwares 
for calculation of KD and Bmax. EBDA is used to perform Scatchard 
transformation(McPherson, 1983) and LIGAND performs an interactive non-
linear curve-fitting(McPherson, 1985).  
A small aliquote of each sample was taken for protein assay (Coomasie Blue 
assay). Different concentrations of bovine serum albumin (BSA) were used to 




6.2.1.4 Coomasie Protein Assay 
Coomasie Brilliant blue is a type of acidic dye with reddish brown color under 
low pH.  When added to protein samples, it forms complexes with amino residues 
of protein via van der Waals forces or ionic interaction. This interaction increases 
pH and stabilizes the dye from cationic form into anionic form, leading to a 
visible spectral shift of color from brown (absorbance ~465nm) to blue 
(absorbance ~610nm). Coomasie protein assay is often performed on microplates 
by mixing small amount of protein samples with Coomasie assay reagent to 
measure absorbance at 640nm, so as to estimate the actual protein concentration 
in each sample.  
As the response to coomasie reagent is non-linear with increasing concentrations 
of proteins, a standard curve needs to be obtained as a reference and assayed 
along with the samples to be tested. Bovine Serum Albumin (BSA) solution is 
usually used to create a standard curve. Stock solution of BSA is prepared at a 









Table 6.4: Serial dilutions of BSA for creating a standard curve 
 Final 
concentration 
of BSA (μg/ml) 
Volume of 1.41 mg/ml 
BSA stock (μl) 
Volume of 
dH2O (μl) 
S1 0 0 1000 
S2 1.41 1 999 
S3 2.82 2 998 
S4 7.05 5 995 
S5 14.1 10 990 
S6 28.2 20 980 
S7 42.3 30 970 
 
Absorbance readings for all eight concentrations of standards are measured at 
640nm according to Coomasie Blue protein assay protocol. Standard curve is 
generated accordingly in order to determine protein concentrations from 
absorbance readings.  
In this assay, 50μl of post-mortem brain tissue homogenate is added with 50μl 
0.5M NaOH to increase membrane protein solubility and reduce the response 
variety of Coomasie reagent to different proteins(Stoscheck, 1990), then further 
diluted with 900μl distilled water into solution (A). 100μl is taken from this 1ml 
(A) and further diluted with 900μl distilled water to form solution (B). 300μl of 
(B) is added with 300μL Coomasie reagent to form solution (C).  (C) is pipetted 
and added in duplicates into 96-well plates and measured absorbance at 640nm 
using Epoch Microplate Spectrophotometer (Bio-Tek).  
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6.2.1.5 Procedural control for freeze-and-thaw effect and postmortem intervals of 
postmortem samples 
Rat brain samples were processed for radioligand binding and Western blot assay 
to determine the effect of the freezing and thawing procedure and longitude of 
postmortem delays on receptor density. Binding/blotting readings are compared 
between freshly processed sample and frozen-and-thawed sample. Also readings 
from samples with different lengths of postmortem interval were compared. 
 
6.2.2 Western blot 
6.2.2.1 Preparation of SDS-PAGE gels 
2 pieces of 10% SDS-PAGE running gels are prepared as previously described in 
Chapter 6.1.3. 10% APS should be freshly prepared before gel making. 300μl 
Isopropanol is gently added onto liquid surface to remove air bubbles. After 
30mins, isopropanol is poured out. Each gel is loaded with SDS-PAGE stacking 
gel solution as described in Chapter 6.1.3. 10-well or 15-well combs are inserted 
into the stacking gel liquid layer instantly. Wait for 10mins or longer and gently 
pull the combs up from the hardened stacking gels. 
6.2.2.2 Cell lysing and harvesting 
To collect cell lysates, boiling Laemmli sample buffer (with β-Mercaptoethanol) 
is used to cover cell monolayers in cell culture plates after collection or aspiration 
of culture medium. Cells can then be harvested by pipetting and boiled at 100 °C. 
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6.2.2.3 Running of Western blot  
SDS-PAGE gels are freshly prepared before Western blot running. Glass plates 
are settled into gel stands and put into running tanks. Fresh running buffer (1x 
buffer diluted 1:10 with RO water from BioRad 10x Tris/Glycine/SDSbuffer) is 
poured in between two plates in one stand as well as outside until an ideal level.  
Western blot samples previously treated with Laemmli buffer is heated at 60 °C 
for 5mins in heating block, and vortexed for 10s before loading. Equal volume of 
samples is loaded into each well.  
6μl of Precision Plus Protein™ Dual Color molecule weight marker (BioRad) is 
loaded into the first well of each gel for monitoring transfer progress and marking 
molecular weights. 
PowerPac™ HC Power Supply (BioRad) electrophoresis transfer machine is used 
for Western blot running. Running voltage is set at 64V for 0.5~1hr, so that 
proteins are finely stacked in the stacking gel layer before entering the running gel 
layer. Running voltage is then increased to 110V and continued for 2~3hrs 
depending on the minimum molecular weight required. 
Before transferring, one piece of blotting paper is soaked in dH2O. Gel plates are 
gently washed with water to remove bubbles.  
iBlot™ Anode Stack, Bottom is settled onto the PowerPac transferring device. 
Gel pieces are placed onto the iBlot™ nitrocellulose or PVDF membrane, and 
covered with filter paper (soaked with dH2O). iBlot™ Cathode Stack is unpacked 
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and placed onto the filter paper. The iBlot™ Disposable Sponge is placed on the 
inner surface of the device lid to absorb excess liquid and impose an even 
pressure onto the transfer stack surface.  
Close the iBlot™ Lid and secure the latch. Select the appropriate program and 
transfer time (P3, 10mins), press the start/stop button to initiate the transferring. 
Upon end of transfer time, press the start/stop button and open the device lid. 
Discard all parts above the membrane (including the gels) and use forceps to 
move the membrane onto a solid surface for labeling. The membrane is then 
incubated in 5% milk PBST for 1hr to reduce nonspecific binding. Binding of 
milk onto unbound membrane sites can optimize sensitivity of primary antibody 
to target proteins by reducing its interaction to nonspecific areas. 
6.2.2.4 Chemiluminescence imaging 
After incubation with 5% milk PBST, membrane is washed 3 times with PBST, 
each time 10mins, and rolled overnight in 3ml 5% BSA in 4 °C cold room with 
appropriate concentration of primary antibody. 
Afterwards, membrane was washed and incubated with appropriate concentration 
of respective HRP-conjugated secondary antibody in 5ml 5% milk PBST for 1hr 
at room temperature.  
HRP (horseradish peroxide) is a type of enzyme widely used to amplify weak 
protein signals. As target proteins were already bound with primary antibody, 
their subsequent association with HRP-conjugated secondary antibody can label 
target proteins with HRP. The Luminata
™
Western HRP Substrates (Millipore) 
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were then directly poured onto the membrane. HRP enzymes linked to target 
proteins can then oxidize HRP substrates, resulting in the production of visible 
light which highlights respective target bands. 
 
Illustration 6.2: Mechanism of HRP-conjugated secondary antibody and 
HRP substrates 
(Picture source: http://www.cellsignal.com/products/images/wb.jpg) 
 
6.2.2.5 Data acquisition and analysis 
Acquisition of Western blot images was performed using Alliance 4.7 
Chemiluminescence Documentation System (UVItec, Cambridge). Analysis of 
Western blot images was performed by calculating relative densities of 
immunoreactive bands, which were expressed as arbitrary units and normalized to 
controls. Controls were included in every blot, treated with vehicle and processed 
in parallel with other conditioned treatments. 
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SPSS 13.0 software (SPSS Inc., USA) was used for statistical analyses. Data were 
tested for normality using Kolmogorov–Smirnov tests, with selection of 
parametric or non-parametric tests for comparisons of variables between groups 
or correlations of variables based on normality of data. Statistical analysis was 
performed using one-way analysis of variance (One-way ANOVA). Null 
hypotheses were rejected at p < 0.05. 
6.2.3 VIVASPIN 
 




VIVASPIN Centrifugal Concentrators (Sartorius) are used to filter and 
concentrate cell culture medium proteins. One set of centrifuge tube is constituted 
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of inner tube and carrier tube. Built with vertical high flux PES membrane, each 
inner tube can be loaded with up to 500µl of medium, located into carrier tube 
(maximum 2.2ml for VIVASPIN 500, VS0122) and centrifuged at high speed in 
fixed angle rotors. Medium proteins with sizes smaller than the membrane’s fixed 
cut-off molecular weight (30kDa for VIVASPIN 500, VS0122) will be filtered 
out of the inner VIVASPIN tube into the carrier tube. The fast ultra-filtration 
allows culture medium to be concentrated from maximum 500µl to a dead-stop 
small volume (e.g. ~25µl for VS0122), which can then be treated with Laemmli 
buffer and measured with Western blot assay.  
 
 





In this assay, each well of 6-well plates is treated with a total volume of 900 µl 
conditioned medium. After treatment, medium samples are collected into 
Eppendorf tubes followed by 15,000g centrifuging for 10mins so as to remove 
cell debris. Out of the total 900 µl, 450 µl is transferred to one VIVASPIN inner 
tube which is located in a 2.2ml carrier tube (the vertical filtration membrane 
facing the center to allow maximum filtration effect). The VIVASPIN tubes are 
centrifuged at 15,000g for 15mins, after which the spinned out medium is 
discarded from the carrier tube. The remaining 450 µl medium is transferred and 
filtered similarly in the same VIVASPIN tube, leaving a final volume of 25 µl 
inside. 500ul dH2O is added into VIVASPIN tube and centrifuged for another 
15mins as a final washing step. 50µl boiling Laemmli buffer is added into each 
VIVASPIN tube, pipetted to mix well and aliquoted into labeled Eppendorf tube, 
boiled for another 5mins and stored in the -20 °C freezer as Western blot samples.  
With the availability of specific antibodies, the VIVASPIN technique enables 
semi-quantitative measurements of soluble proteins in the cell culture medium. 
6.2.4 Cell Proliferation Assay (MTS) 
Cells are plated in duplicates in 96-well cell culture plates and allowed to grow 
for 24hs. Cell medium in each well is then replaced by 100µl conditioned 
treatment medium and incubated for required length of time.  
10µl CellTiter 96
®
 AQueous One Solution Reagent is pipetted into each well. The 
plate is incubated for another 2~4hrs in 37°C, 5% CO2 incubator. Absorbance is 
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read at 490nm using Epoch Microplate Spectrophotometer (BioTek Instruments, 
Inc.).  
Proportion of viable cells is calculated as mean absorbance of tested wells divided 
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Cortical Histaminergic H3 receptors in Ischemic Vascular and 
Mixed Dementia 
7.1 Introduction 
Vascular dementia (VaD) is the second most common type of dementia after 
Alzheimer’s disease(Erkinjuntti et al., 2004). Cerebrovascular events (e.g. stroke) 
may cause ischemic, hypoperfusive or haemorrhagic conditions in the brain which 
block supply of blood and oxygen, and finally induce alterations in brain structure 
(e.g. tissue necrosis and lesions) and related functions (e.g. cognitive and 
executive symptoms).Unlike insidious and progressive decline of cognition in AD, 
VaD patients often suffer from an abrupt or stepwise deterioration of cognition 
after stroke. Clinical diagnosis of VaD requires the co-existence of vascular 
deficits in the brain (large or small vessel disease, microinfarcts, lacunes, white 
matter lesions etc.) together with AD neuropathological hallmarks of amyloid 
plaque deposits and neurofibrillary tangles. 
Several subtypes of VaD have been described based on differences in size, 
number and location of infarcts and lesions. Subcortical ischemic vascular 
dementia (SIVD) is a relatively homogenous subtype of vascular dementia, 
pathologically characterized by frontal deficits (e.g., executive dysfunction), 
small-vessel diseases-induced white matter lesions, and relatively mild dementia. 
Clinical presentations of SIVD include damaged executive and motor function, 
memory and mood, which can be related to the disrupted frontal-subcortical 
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circuits caused by ischemic lacunes and lesions(Ishii et al., 1986)(Roman et al., 
2002). Mixed dementia is often referred to as combined pathology of AD and 
VaD. Due to limited accuracy of clinical diagnostic criteria and frequent 
misdiagnosis of mixed patients as AD or other dementia, mixed dementia (MIX) 
may have a higher prevalence than currently recognized, and may become 
increasingly common in elderly patients.  
While cholinesterase inhibitors (ChEIs) and glutamate receptor antagonist 
Memantine have been widely approved and applied for treatment of AD, there are 
no specifically approved pharmacological treatments for VaD and mix. ChEIs and 
Memantine have been tested in clinical trials of VaD patients for their 
effectiveness of increasing neurotransmission and ameliorating cognitive 
symptoms, however these clinical trials have only shown moderate improvements 
with unclear significance.  
The lack of commonly accepted diagnostic criteria and effective treatments makes 
further studies on VaD and MIX necessary and urgent. While investigations on 
novel biomarkers might provide novel insights and stronger support for higher 
accuracy of diagnosis, such as identifying inflammatory markers that are 
significantly associated with post-stroke cognitive decline(Narasimhalu et al., 
2013), larger clinical trials using traditional AD medications on VaD and MIX 
patients are required for better evaluation of their therapeutic effects. Meanwhile, 
characterization of other neurotransmitter systems still remains important so as to 
better understand the neurochemical alterations under disease conditions and 
uncover novel therapeutic targets for VaD and MIX patients. 
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Studies on Histaminergic H3 receptors have attracted research interest on their 
potential role as novel therapeutic targets for treating dementia symptoms.  
Histaminergic neurons are located exclusively in the tuberomamillary nucleus of 
the posterior hypothalamus and have a widespread projection throughout the CNS. 
The neurotransmitter histamine is known to interact with four subtypes of G-
protein coupled histaminergic receptors, H1-H4(Brown et al., 2001). 
Histaminergic H3 receptors have been characterized to locate on both 
histaminergic neurons and other types of neurons, inhibiting the release of 
histamine as presynaptic autoreceptors, and also suppressing other 
neurotransmitters (acetylcholine, dopamine, GABA, serotonin, glutamine, etc.) as 
presynaptic heteroreceptors(Haas et al., 2008).   
This neuromodulatory role of Histaminergic H3 receptors has attracted much 
attention for treatment of CNS diseases because of its potency to modulate 
multiple target systems instead of only histamine system. H3 antagonists/inverse 
agonists have been tested in animal models and also in clinical trials showing 
ameliorative effect on memory and cognitive deficits in neurodegenerative 
diseases(Miyazaki et al., 1997)(Medhurst et al., 2007)(Pascoli et al., 2009)(Bitner 
et al., February)(Nowak et al., 2008). With abundant expression in brain areas 
related to cognition, such as hippocampus, caudate, putamen, frontal cortex, but 
low level in peripheral organs such as heart, lung, liver(Brioni et al., 2011), 
Histaminergic H3 receptors are considered to be a potential CNS target with low 
peripheral side effects.    
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Our previous studies have identified the relatively intact status of Histaminegic H3 
receptors in AD cohorts, in which higher H3 receptor density in the frontal cortex 
was correlated with worse severity of dementia symptoms, indicating their 
potential utility as AD therapeutic targets(Medhurst et al., 2007, p. 189254). 
However, status of Histaminergic H3 receptors remains to be explored in VaD and 
mixed dementia patients. As previously described, SIVD patients are 
characterized by deficits in the frontal cortex and damages of related executive 
functions. It would be interesting to characterize the status of H3 receptors 
especially in the frontal lobe, to see whether the receptors are also associated with 
the frontal deficits and are potential therapeutic targets for cognitive impairments 
in SIVD as well. 
In this study, the major objective of research was to explore the status of 
Histaminergic H3 receptors in SIVD/MIX and their potential utility as a novel 
therapeutic target. Hypotheses of this project include: 
1) Histaminergic H3 receptors are preserved in SIVD/MIX brain regions, 
such as the frontal cortex; 
2) Histaminergic H3 receptor density is correlated with cognitive outcomes, 
such as pre-death MMSE scores. 
In this study, we measured Histaminergic H3 receptors in post-mortem brains of a 
longitudinally assessed cohort of SIVD and mixed SIVD/AD (MIX) patients 
using radioligand saturation assay, and investigated potential correlations between 
H3 density and clinical parameters.  
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7.2 Materials and methods 
7.2.1 Patients and clinical assessments 
All studies described in this thesis have been approved by Singapore Institutional 
Review Board (IRB). In this study, patients were recruited from Oxford Project to 
Investigate Memory and Ageing (OPTIMA, see 
http://www.medsci.ox.ac.uk/optima), a longitudinal study of dementia and ageing, 
whose postmortem tissues are now part of the Thomas Willis Oxford Brain 
Collection. Most patients from OPTIMA received assessments every year since 
the start of recruitment and until death, including cognitive assessments 
(CAMCOG, a self-contained cognitive part of the Cambridge Examination for 
Mental Disorders of the Elderly (CAMDEX). CAMCOG assessments incorporate 
all the examination items in the Mini-Mental State Examination (MMSE) as well 
as additional tests on functions such as attention, perception, orientation etc.  
Informed consent was obtained from family members before collection of brain 
tissue. Tissue blocks from one hemisphere were dissected and fresh frozen, while 
the contralateral hemisphere was treated with formalin and processed for 
pathological assessments.  
The NINDS-AIREN criteria was applied for diagnosis of vascular dementia, 
while determination of SIVD was based on neuropathological evidence of 
microinfarcts, lacunae, white matter and small vessel disease in subcortical 
structures. In addition to SIVD diagnosis, mixed dementia patients (with mixed 
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SIVD and AD) were identified to fit with “probable” or “definite” AD diagnosis 
according to the CERAD criteria. 
Braak staging was used to record neurofibrillary tangle burdens in the brain. All 
control patients died from non-neurological causes, had no history of dementia or 
psychiatric symptoms, and do not satisfy neuropathological criteria for 
neurodegenerative diseases. Depending on tissue availability, not all assays were 
performed on all subjects. 
7.2.2 Radioligand and chemicals 
Tritiated GSK189254 (6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7- 
yl)oxy] -N-methyl-3-pyridinecarboxamidehydrochloride; speciﬁc activity 81.0 Ci 
/mmol) was prepared through a contract with GE Healthcare, UK. Thioperamide 
maleate was purchased from Tocris Bioscience, UK as non-radioactive H3 
receptor blocker. All other chemicals were from Sigma-Aldrich Co. (USA) and of 
reagent grade. 
7.2.3 Tissue processing 
Brain tissues were thawed on ice, dissected free of white matters and meninges, 
and homogenized with a Polytron Ultra-Turrax homogenizer (10s at maximum 
setting) and washed with ice-cold 50mM Tris-HCl buffer, pH 7.4. The 
homogenates were stored in -80 °C freezer.  
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In this study, Brodmann areas 9 and 46 samples from the dorsolateral prefrontal 
cortex were selected, while hippocampal tissues include CA1-CA3 as well as the 
dentate gyrus. 
 




7.2.4 Radioligand Saturation Binding Assay 
As previously described in Chapter 6.1.1, brain tissue homogenates were thawed 
on ice. For each sample, half of total amount of homogenate was added into assay 
tube in triplicates and diluted 1:3 vol/vol with assay buffer (50 mM Tris-HCl, pH 
7.4), after which 6 - 7 concentrations (0.05-5 nM) of [
3
H]GSK189254 were added 
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into assay tube in triplicates. Total volume of assay (500 μl) was constituted by 
1/5 brain homogenate, 3/5 assay buffer, and 1/5 radioligand. Incubation time was 
1h at room temperature before subsequent scintillant reading. The other half 
amount of homogenate was used for a parallel assay, in which total volume of the 
assay (500 μl) was constituted of 1/5 brain homogenate, 2/5 assay buffer, 1/5 
radioligand, and 1/5 10μM unlabelled thioperamide maleate to define non-specific 
binding. An aliquot of the diluted homogenate was used to measure protein 
concentration using Coomasie Protein Assay (Pierce Coomasie Plus, Thermo 
Fisher Scientific, USA). 
Incubation was terminated by rapid filtration in a cell harvester (Molecular 
Devices, USA) with ice-cold sodium phosphate buffer through 0.1% 
polyethylenemine-treated Whatman GF/B glassfibre filters (GE Healthcare, USA), 
then air-dried and punched into scintillation vials for the measurement of 
membrane-bound radioactivity using liquid scintillation spectrometry with a 
Wallac Β counter (PerkinElmer, USA). 
7.2.5 Statistical analysis 
Scatchard transformation of radioligand binding data was performed using EBDA 
and LIGAND software to calculate KD (binding affinity, in pM) and Bmax (binding 
density, in fmol / mg protein). In all cases, binding isotherms were best fitted to 
single sites with Hill coefficients (NH) around 1. Statistical analyses were 
performed using SPSS 13.0 for Windows software (SPSS Inc, USA), with 
normality of data tested by Komogorov-Smirnov tests. Since the sample sizes of 
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the groups were unequal, comparisons of normally distributed variables between 
control, SIVD and MIX were performed by one-way analyses of variance 
(ANOVA) followed by post-hoc Tamhane’s T2 tests. Pearson’s product moment 
was used in correlations of neurochemical variables with dementia severity 
(defined as mean CAMCOG and MMSE scores up to one year pre-death). 
Appropriate non-parametric tests were used for ordinal or non-normally 
















7.3.1 Demographic and disease variables in controls and dementia patients 
Table 7.1: Demographic and disease variables of controls and dementia 
patients 
  Control SIVD  MIX         
Demographics         
    Maximum number of cases  12 15 6 
    Age at Death (years)  80.7 ± 2 84.0 ± 2  75 ± 4  
    Sex (Male/Female) 8M / 4F 10M / 5F 3M / 3F 
    Follow-up (years) 4.1 ± 0.7 4.7 ± 0.7 3.6 ± 0.6 
    Postmortem Interval (hours) 60 ± 10 53 ± 9 39 ± 7 
Disease variables        
Predeath CAMCOGtotal score 94.5  ± 3.4 75.8 ± 4.9* 20.1 ± 11** 
    Predeath MMSE score    27.8  ± 0.6 22.6 ± 1.5*  5.1 ± 2.9**  















Table 7.1 shows that age, length of follow-up and postmortem interval were 
matched among groups (ANOVA with post-hoc Tamhane, p> 0.05). Data are 
mean ± S.E.M. CAMCOG, Cambridge Cognitive Examination total scores; 
MMSE, Mini-Mental State Examination scores. 
 
There are more males than females in both controls and SIVD, but neurochemical 
variables were not significantly different between male and female groups 
(Student’s t tests, p> 0.05, data not shown).  
As expected, most SIVD patients had little neurofibrillary tangle burden (Braak 
stage 0 – II, while none was higher than Braak stage III / IV). In contrast, all MIX 
patients had extensive deposition of tangles indicated by Braak stage V/VI.  
SIVD patients showed significantly lower cognitive function scores than control, 
although their conditions were considered milder than MIX patients, who showed 
significantly lower pre-death MMSE and CAMCOG scores compared to SIVD.  
7.3.2 [
3
H]GSK189254 binding to H3 receptors in Controls, SIVD and MIX 
 
Figure 7.1  [
3
H]GSK189254 binding to postmortem cortex of control, SIVD 
and MIX subjects.  (A), representative saturation binding isotherm of 
[
3
H]GSK189254 in control frontal cortex, with KD = 0.16 nM and Bmax = 24.3 
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fmol / mg protein. (B), bar graphs of mean ± S.E.M. binding density (Bmax) values. 
Available N for controls, SIVD and MIX are: Frontal cortex (11, 14, 5), AC (4, 10, 
4), Hipp (4, 7, 4). AC, anterior cingulate gyrus; Hipp, hippocampus; MIX, mixed 
dementia (SIVD / AD); SIVD, subcortical ischemic vascular dementia. 
*Significantly different from SIVD (ANOVA with post-hoc Tamhane, p< 0.05). 
 
Binding of histamine H3 receptors in post-mortem brain with [
3
H]GSK189254 
was of high specificity (> 90% total binding at concentrations around KD) with 
Hill coefficients (NH) around 1 and calculated mean affinity constant (KD) values 
ranging from 0.04 – 0.11 nM. Given the maximum radioligand concentration of 5 
nM, the data suggest that H3 sites are fully saturated under our assay conditions. 
KD values of SIVD and MIX were not significantly different from controls, and 
also did not vary across the brain regions studied (p> 0.05, data not shown).  
For binding densities, Figure 7.1B shows that the relative densities of H3 
receptors seem to be frontal cortex ≈ anterior cingulate > hippocampus, in 
agreement with previous autoradiography studies (Medhurst et al., 2007). The 
Bmax of mixed dementia was significantly higher than SIVD in the anterior 
cingulate. However, both MIX and SIVD Bmax values showed only non-
significant trends toward increases compared to controls in all regions studied 







7.3.3 Correlation of H3 receptor densities with cognitive scores 
 
Figure 7.2 Scatter plots of [
3
H]GSK189254 binding to H3 receptors in the 
frontal cortex and pre-death cognitive scores with linearly regressed best fit 
line. CAMCOG, Cambridge Cognitive Examination total scores; MMSE, Mini-
Mental State Examination scores. Available N = 26-27.  
*, Significant Pearson correlation. 
 
The association between Histaminergic H3 receptor densities and cognition was 
studied in the frontal cortex, which has well-established roles in cognition and the 
highest available N in our study. Figure 7.2 shows that H3 receptor Bmax   
negatively correlated with predeath MMSE scores, while similar, non-significant 







Histaminergic H3 receptors have attracted much attention as a potential 
therapeutic target for treating neurodegenerative diseases because of its 
modulatory role on the release of many neurotransmitters that are involved in 
cognition, memory and other higher mental functions. Moreover, its abundant 
expression in brain and limited peripheral distribution reduces risks of adverse 
peripheral side-effects and higher selectivity toward CNS disorders.  
Selective Histaminergic H3 receptor antagonists are being studied for their effects 
of up-regulating cognition-related neurotransmitter level. We have previously 
reported the relatively intact status of H3 receptors in Alzheimer’s disease 
compared to controls, and higher H3 receptor density in the frontal cortex was 
correlated with more severe dementia prior to death(Medhurst et al., 2009). These 
data indicate that antagonisms of H3 receptors may be beneficial for the treatment 
of AD patients. However, studies of H3 receptor status in other types of dementia 
are to be explored on whether H3 receptors can serve as potential drug targets in 
other neurodegenerative disorders as well.  
In this project, we used radioligand saturation binding assay to study the 
Histaminergic H3 receptor expression in SIVD and MIX patients, using post-
mortem samples from three brain regions: frontal cortex, anterior cingulate gyrus 
and hippocampus. H3 receptors are relatively preserved in SIVD compared to 
control group in all three brain areas, while mixed dementia group shows an 
 107 
 
insignificant increase, suggesting that H3 receptors are not significantly affected 
by subcortical vascular pathology.  
In the anterior cingulate region, H3 density in SIVD group is significantly lower 
than MIX group, of which the underlying mechanisms remain to be elucidated. 
We may speculate that, although both groups did not show significant differences 
from control in this study, the higher density of H3 receptors in MIX than in SIVD 
may likely contribute to the apparently worse pre-death cognitive status in MIX 
than SIVD, indicated by much lower MMSE and CAMCOG scores.  
Furthermore, frontal cortex H3 receptor expression was negatively correlated with 
pre-death MMSE scores, indicating that higher H3 receptor density can be related 
to worse status of cognition. This observation is generally consistent with the 
negative modulatory role of H3 receptors on histaminergic as well as other 
neurotransmitter systems, such as cholinergic and dopaminergic system. 
Therefore, our data suggest that the potential therapeutic utility of H3 receptor 
antagonists may be extended to SIVD and MIX due to availability of the drug 
target, and recommend the inclusion of these diseases in future clinical trials.  
There are a few limitations of this study. Firstly, significant correlation between 
H3 density and MMSE was characterized but not with CAMCOG, though 
CAMCOG showed a similar trend of negative correlation with H3 density with a p 
value (0.066). Similarly, MIX patients showed a tendency of H3 increase 
compared to controls in all the brain regions studied, though the differences were 
not statistically significant. Larger studies with more number of samples are 
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recommended to further explore these potential correlations or alterations to 
confirm their clinical significance. 
Another limitation is that only SIVD and mixed SIVD/AD cases were selected for 
study considering their relatively homogenous clinical presentation and lack of 
significant vascular pathology in the brain areas studied. Further studies using 
tissue samples from other subtypes of VaD/MIX are required before making 
assumptions that H3 receptor antagonists are also applicable to treat other 
subtypes. 
Also, the potential heterogeneity of dementia severity in two brain hemispheres 
(i.e. the hemisphere used for neurochemical characterization and the contralateral 
one used for neurohistological assessments), may restrict the accuracy and 
reliability of the biochemical findings and their correlations with 
neuropathological and clinical variables. According to the OPTIMA cohort 
protocol, the two brain hemispheres were processed separately under different 
methodologies (dissected and fresh frozen for neurochemical analysis, and 
formalin fixed for histopathological examinations). Therefore, performances of 
neurochemical and neuropathological assessments in the same area of the same 
hemisphere were not achievable.  An alternative strategy to overcome this 
limitation is to use immunohistochemical staining instead of Western blot as the 
biochemical identification method of Histaminergic H3 receptor expression in 
specific brain regions. Post-mortem human brain tissue can be perfusion-fixed 
and dissected into different blocks which belong to specific Brodmann areas. 
Using microtomy, each tissue block can be cut into a series of adjacent sections 
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which belong to the same cortical region of the same patient. With the availability 
of selective antibodies, immunohistological staining can then be performed on the 
brain sections to identify the status of target receptors, while histological 
evaluations for neuropathological hallmarks and lesions in the same brain region 
are also achievable with the availability of an adjacent section. Although results 
from immunohistochemical staining can not provide a quantitative measurement 
of specific receptors, they can maintain relatively better consistency with 
neuropathological assessments while still allowing comparisons between different 
diagnostic groups.  
In summary, this study is the first report of Histaminergic H3 receptor status in 
frontal cortex, hippocampus as well as anterior cingulate of subcortical ischemic 
vascular dementia (SIVD) as well as mixed SIVD and AD (MIX) patients. H3 
receptors are relatively preserved in all regions studied, and the only significant 
difference is between SIVD and MIX in the area of anterior cingulate. Moreover, 
higher frontal cortex H3 receptor density was significantly correlated with lower 
pre-death cognitive function. The intact status of H3 receptors as well as their 
negative correlation with cognitive scores support the potential utility of H3 
receptor antagonists as therapeutic targets in treatment of SIVD and mixed 
dementia. However, further confirmatory studies using larger cohorts are needed, 
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Cortical Cannabinoid CB1 Receptors in Parkinson’s Disease 
Dementia and Dementia with Lewy Bodies 
8.1 Introduction 
The term ‘Lewy body dementia’ (LBD) refers to a subtype of dementia with 
overlapping symptoms of Parkinsonism and cognitive deficits, and the 
neuropathological hallmarks of Lewy body deposition in the brain(Mattila et al., 
2000)(Zarranz et al., 2004). Besides motor signs and symptoms typical of 
Parkinsonism, such as rigidity, muscle stiffness and tremors, LBD patients present 
with cognitive symptoms : clinical deterioration of memory, decline of cognitive 
functions, as well as psychiatric symptoms of depression, visual hallucinations 
and delusions(Ballard et al., 1999).There are two common subtypes of LBD: 
Parkinson’s Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB). 
Diagnostic differentiation between PDD and DLB has been difficult due to their 
similarities in clinical presentations and known neurochemical alterations. 
The potential utility of Alzheimer’s disease medications in treating LBD has been 
explored. Limited efficacy in improving cognitive outcomes and psychiatric 
factors(Dubois et al., 2012) as well as worsening of peripheral side effects such as 
gastrointestinal disorders, nausea and body tremor(Emre et al., 2004) have been 
reported in clinical trials testing cholinesterase inhibitors in LBD patients. 
Clinical trials of Memantine have also shown conflicting results of therapeutic 
effect but deterioration of psychiatric symptoms(Ridha et al., 2005)(Sabbagh et al., 
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2005)(Mathys et al., 2013)(Takaya et al., 2013). Therefore, exploration for novel 
therapeutic targets of LBD remains necessary, which requires a clearer 
understanding of the neurochemical status of LBD. 
Evidence suggests that the activation of Cannabinoid CB1 receptors might be 
beneficial for treatment of neurodegenerative diseases. Abundantly expressed at 
presynaptic terminals in CNS, CB1 receptors are highly involved in cognitive 
functions because of their retrograde modulation of neurotransmitter release as 
well as G-protein related downstream signaling. Our previous study showed that 
in postmortem brain samples of Alzheimer’s disease patients, frontal CB1 level 
was positively correlated with pre-death cognition scores(Lee et al., 2010), 
indicating the potential role of CB1 receptors in preserving cognitive function. 
Furthermore, CB1 activation has been suggested neuroprotective in various 
aspects, including ameliorating Aβ neurotoxicity(Haghani et al., 2012a), 
promoting neurogenesis and neurotrophin release(Williams et al., 2003), and 
producing anti-depressant and anxiolytic effects(Casarotto et al., 2012). However, 
the status of CB1 receptors in LBD patients remains unclear. In this study, we 
used Western blotting assay to measure the expression of CB1 receptors in 
postmortem brain samples of a longitudinally assessed cohort of PDD and DLB 
patients. 
In this study, the major objective of research was to explore the status of 
Cannabinoid CB1 receptors and their potential utility as a novel therapeutic target 
in PDD/DLB patients. Hypotheses of this project include: 
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1) Cannabinoid CB1 receptors are preserved in PDD/DLB brains compared 
to controls, such as in the frontal and temporal cortexes; 
2) Cannabinoid CB1 receptors are associated with neurochemical & 
neuropathological outcomes of PDD/DLB patients, such as burden of 
plaques and tangles.   
 
8.2 Materials and methods 
8.2.1 Clinical recruitment and data collection 
In this study, LBD as well as non-demented control patients were recruited from 
the Brains for Dementia Research (BDR) Initiative 
(http://www.brainsfordementiaresearch.org.uk/). Measurement of patients’ 
cognitive status was performed during clinical observations (usually 8~10 years 
before death) by recording Mini-Mental State Examination (MMSE) scores. 
Clinical diagnosis of PDD was made when Parkinsonism occurred more than one 
year earlier than dementia, while diagnosis of DLB was decided when dementia 
symptoms of cognitive decline or neuropsychiatric disorders (e.g. hallucination) 
happened before or within one year of Parkinsonism(McKeith et al., 1996).  
Postmortem brain tissues were provided by the University Hospital Stavanger, 
Newcastle University and the Thomas Willis Oxford Brain Collection and 
the London Neurodegenerative Diseases Brain Bank. Informed consent was 
obtained before collection of brain tissue with ethical approval. Samples from 
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Brodmann area 9 (frontal cortex) and 21 (lateral temporal cortex) were selected 
for study because of their involvement in multiple higher cognitive functions such 
as memory, executive function, attention, reward etc. Tissue blocks from one 
hemisphere were dissected and fresh frozen, while the contralateral hemisphere 
was treated with formalin and processed for pathological assessments, which 
enables the research correlation between neurochemical results and clinical 
parameters. Assessment of neuropathological markers was performed according 
to standardized criteria, e.g. Braak & Braak staging for evaluation of 
neurofibrillary tangle burdens, CERAD scores for frequencies of senile plaques, 
and cortical Lewy body scores for cortical deposition of Lewy bodies. All control 
patients died from non-neurological causes, had no history of dementia or 
psychiatric symptoms, and do not satisfy neuropathological criteria for 
neurodegenerative diseases with only mild age-related neuropathological changes 
(e.g., neurofibrillary tangle Braak stage <3). 
 
8.2.2 Tissue processing 
For each patient, 500mg sample of frozen tissue was taken from Brodmann Area 
9 (dorsolateral prefrontal cortex) and 21(middle temporal gyrus) respectively. 
Menings, white matter, blood vessels and clots were dissected from the frozen 
tissue to leave approximately 200mg of grey matter, which was homogenized 




Protein concentration was measured using the Coomasie (Bradford) Protein Assay 
Kit (Thermo Scientific) and read in duplicates at 640nm using Epoch Microplate 
Spectrophotometer (Bio-Tek). Protein concentration for each sample was 
calculated according to a BSA standard curve ran at the same time with samples. 
Laemmli sample buffer (Bio-Rad Laboratories, USA) were added into each 
sample tube according to protein assay readings to obtain the same final protein 
concentration. In subsequent Western blotting performance, equal volume of each 
sample was loaded into the respective wells. 
8.2.3 Chemicals 
Chemical reagents were purchased from Sigma-Aldrich Co. (USA) and of 
analytical grade.  
8.2.4 Neurochemical measurements by Western blot 
 BA9 and BA21 homogenates were separated on 7.5% polyacrylamide gels, 
transferred onto PVDF membranes using iBlot™ Gel Transfer Device (Invitrogen 
Life Science Technologies). The primary antibodies used was CB1 receptor 
antibody (catalog number PA1745, rabbit polyclonal anti-Cannabinoid Receptor 1 
Thermo Scientific* Pierce, Rockford, IL, USA. Dilution was 1:500 in BSA). CB1 
density from each sample is quantified as fold reading of external control loaded 
in the same gel. A spare sample of postmortem human brain tissue was used as 
external control. 
Immunoreactive bands were visualized using enhanced chemiluminescence and 
quantified using UVIsoft Image quantification software (UVItec, UK). 
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Membranes were stripped and reblotted with anti-β-actin primary antibody 
(1:5000) for loading control. One lane of external standard consisting of fixed 
amounts of protein from a specific sample was loaded in each blot to enable 
normalization of data. Normalized immunoblot optical densities were expressed 
in arbitrary units. 
8.2.5 Statistical Analysis 
Statistical analyses were performed using SPSS 10.0 for Windows. Relationships 
between CB1 receptor immunoreactivity and potential confounding factors 
(demographics or disease parameters) were analyzed with stepwise multiple 
regress. CB1 receptor immunoreactivities of non-demented controls and disease 
groups (PDD and DLB) were compared using one-way ANOVA, followed by 
post-hoc tests. Differences were considered significant if p value <0.05. 




8.3.1 Demographic and disease variables in controls and dementia patients 
A total number of 79 IDs in the BDR cohort were selected for study, including 21 
controls, 30 PDD and 28 DLB cases. In control group, two IDs (A401 and A185) 
had no availability of BA21 sample, and one ID (A61) had no BA9. So the N for 
control group is 20 for BA9, and 19 for BA21. 
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Table 8.1 shows demographic data for control patients, 30 PDD patients and 28 
DLB patients selected for study. In each area, three diagnostic groups were 
matched in age, gender and post-mortem delay (one-way ANOVA, p>0.05). 
As expected, patients from the PDD and DLB groups have cognitive deficits 
varying from Mild Cognitive Impairment (MCI) to severe dementia according to 
their MMSE test scores (from a total score of 30, MMSE 27~30 indicates normal 
or MCI; 20~26 indicates mild dementia; 10~20 moderate dementia; <10 severe 
dementia; NICE technology appraisal guidance 2011, TA217).  PDD and DLB 
groups also have a larger proportion of CERAD 'moderate' or 'frequent' 
classification compared to controls, indicating a higher frequency of senile 
plaques. The DLB group has a relatively higher percentage of patients in Braak 
stage 5~6 (10 of 28) compared to control (0 of 16) as well as PDD group (1 of 30), 












Table 8.1   










Maximum number of cases 




















Braak Staging   0~2 12 12 21 5 
3~4 4 2 8 13 
5~6 0 0 1 10 
Missing  4 5 0 0 
CERAD  none 10  10  12 1 
sparse 3 2 10 6 
moderate 0 0 4 9 
frequent 0 0 4 12 
missing 7 7 0 0 
      
MMSE control 20 19 0 0 
MCI 0 0 4 5 
Mild 0 0 5 5 
Moderate 0 0 9 9 
 Severe 0 0 11 6 




Data are mean ± S.E.M. CERAD, Consortium to Establish a Registry for 
Alzheimer's Disease; MMSE, Mini-Mental State Examination scores. 
 
8.3.2 CB1 receptor density in BA9 and BA21 of PDD & DLB patients 
 













Figure 8.1 shows that, in all the diagnostic groups (control, PDD, DLB), CB1 
expressions in BA9 were significantly higher than BA21. This result was 
consistent with previous findings of a relatively higher level of CB1 in the frontal 





Figure 8.1: CB1 receptor immunoreactivity in BA9 and BA21. CB1 density 
from each sample is quantified as fold reading of external control loaded in the 
same gel so as to enable cross comparisons between different blots. Bar charts 
show mean ± S.E.M. As described in 8.3.1, three control IDs either without BA9 
or without BA21 availability were excluded. Available N for each group: control 
(18), PDD (30), DLB (28). ***, significant difference, Student’s t-test, p < 0.001. 
 
Figure 8.2 shows that, in BA9, both PDD and DLB groups showed non-
significant trends toward decreasing of CB1R density compared to control group 
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(ANOVA with post-hoc Tamhane, p=0.06); in BA21 however, the PDD group 
shows significantly lower CB1 density than control (ANOVA with post-hoc 




Figure 8.2: CB1 receptor immunoreactivity in control, PDD and DLB brains. 
(A) Representative blot of CB1 receptor expression in BA21. CB1 density from 
each sample is quantified as fold reading of external control loaded in the same 
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gel so as to enable cross comparisons between different blots. Bar charts show 
mean ± S.E.M. (B) Representative immunoblots of CB1 receptor in BA21, with 
“C” denoting controls, “P” denoting PDD subjects, and “D” denoting DLB 
subjects. “E” stands for external control, which every blot is loaded with the same 
amount to enable quantitative analysis of results from multiple blots. Available N 
for each group: control (20 for BA9, 19 for BA21), PDD (30), DLB (28). *: 
Significantly different from control, One-way ANOVA, p < 0.05. 
 
8.3.3 Correlations of CB1 receptor density with clinical and neurochemical 
parameters 
Information on clinical and neurochemical parameters was obtained from the 
BDR database. Some neurochemical measurements and clinical data were 
contributed by our collaborators from UK, including the neuropathological 
assessments of Lewy body scores, Braak staging and synaptophysin expression in 
this study. 
No significant correlation was found between CB1 receptor density with cortical 
Lewy body scores (p=0.79 for BA9 and 0.2 for BA21) or Braak staging scores 
(p=0.6 for BA9 and 0.48 for BA21), indicating that the status of CB1 receptors 
was not affected by neurofibrillary tangles or Lewy body pathology.  
As shown in Figure 8.3, patients with senile plaque burdens (extracellular 
deposits of Aβ peptides, CERAD coding=sparse/moderate/frequent) did not 
present with a significantly different level of CB1 compared to patients with no 
senile plaques (CERAD coding=none). However in BA9, there is a tendency of 
CB1 reduction in patients with moderate or heavy burdens of plaque compared to 
those without plaques. Furthermore, patients with moderate frequency of plaques 
seemed to have significantly less CB1.in BA9 than those with only sparse plaques. 
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It is possible that during the process of neuropathological Aβ accumulation, 
frontal cortex CB1 receptors of LBD patients can be affected. The underlying 
mechanism is yet to be elucidated but is possibly related to suppression of CB1 
transcription by Aβ (Esposito et al., 2007). On the other hand, the loss of CB1 
receptor signaling might also have played a role in accelerating the accumulated 
formation and deposition of Aβ. 
 
Figure 8.3: CB1 receptor immunoreactivity in postmortem samples with 
different extent of senile plaque burdens. CB1 density from each sample is 
quantified as fold reading of external control loaded in the same gel. Bar charts 
show mean ± S.E.M. of CB1 receptor immunoreactivities normalized to β-actin. 
Available N values are: CERAD coded (senile plaque frequency) none=24, 
sparse=19, moderate=13, frequent=16. *: Significantly different, One-way 
ANOVA with post hoc Bonferroni, p < 0.05. 
 
Possible associations between CB1 receptor density and available neurochemical 
parameters from the BDR database were also explored, among which the 
correlation with synaptophysin was greatest. Western blot measurement of 
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synaptophysin expression (using rabbit monoclonal antibody, ab32127 AbCam) 
was performed by our collaborator Paul T. Francis lab from King’s College 
London, UK. 
20 controls, 28 PDD and 15 DLB patients had data availability of both CB1 BA9 
density and synaptophysin BA9 expression, so a total of 63 patients were pooled 
for comparison of synaptophysin between diagnosis groups as well as correlation 
withCB1. Table 8.2 shows that, in BA9, synaptophysin level was significantly 
lower in PDD group compared to both control (ANOVA with post-hoc Tamhane 
p<0.001) and DLB (ANOVA with post-hoc Tamhane p=0.03). Significant 
difference was not observed between control and PDD group (ANOVA with post-
hoc Tamhane p>0.05). 
Table 8.2 
Expression of synaptophysin in BA9 of control, PDD and DLB brains 
 Control  PDD  DLB  
Number of cases 20 28 15 
synaptophysin 0.011±0.022 -0.132±0.020** -0.041±0.026 
**: Significantly different from control, One-way ANOVA, p < 0.01. 
 
Figure 8.4 shows that CB1 receptor density was significantly correlated with 
synaptophysin expression in BA9 with moderate-to-strong strength. (Pearson 





Figure 8.4 Correlation of Cannabinoid CB1 receptor densities with 
synaptophysin expression in BA9. Scatter plots of normalized BA9 CB1 
receptor immunoreactivity and synaptophysin expression with linearly regressed 
best fit lines. CB1 density from each sample is quantified as fold reading of 
external control loaded in the same gel. *, significant Pearson correlation. 
 
8.4 Discussion 
As an abundantly expressed neurotransmitter receptor in the central nervous 
system, Cannabinoid CB1 receptor has been of great research interest because of 
its neuromodulatory role on controlling the release of crucial neurotransmitters 
involved in cognitive function. Reduction of CB1 receptor in AD brains has been 
reported in various brain regions(Ramirez et al., 2005)(Westlake et al., 1994), 
although unaltered status has also been reported(Lee et al., 2010). However, there 
has not been detailed characterization of CB1 receptor status in many other types 
of dementia such as Lewy body Dementia.  
This study provides novel evidence that there is a significant neurochemical 
reduction of Cannabinoid CB1 receptor expression in post-mortem temporal 
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cortex (BA21) of PDD patients, as compared to both non-demented control and 
DLB group, indicating the potential role of CB1 receptor as a marker for 
diagnostic differentiation between PDD and DLB.  
While BA9 CB1 receptor density in PDD group was not statistically different 
from controls (p=0.06), significant reduction of BA9 synaptophysin level was 
observed compared to control (p<0.001) as well as DLB group (p=0.03). These 
results indicate worse presynaptic deficits in PDD than DLB. Although the 
underlying mechanisms remain unclear, we may speculate that the similar extent 
of reduction of CB1 receptor in BA9 somehow contributes to different severity of 
synaptic deficits between PDD and DLB.  
Furthermore, when all BA9 samples are pooled for analysis, a significant 
correlation between BA9 CB1R density and synaptophysin was observed with 
moderate-to-strong strength. This correlation indicates the potential involvement 
of CB1 receptor in synaptic functions in the frontal cortex. 
As a presynaptic vesicle glycoprotein, synaptophysin is expressed in all neurons 
in the brain and is often used as a marker for presynaptic neuronal terminals. 
Located at the surface of presynaptic neuron vesicles, synaptophysin interacts 
with the SNARE complex to modulate the docking and fusion of presynaptic 
vesicles, control neurotransmitter release and promote inter-synaptic 
communication(Harbury, 1998). In studies of AD patients, synaptophysin has 
been observed to be significantly reduced compared to controls(Hamos et al., 
1989)(Masliah et al., 1991)(Sze et al., 1997), and has been strongly correlated 
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with severity of dementia. In previous PDD and DLB studies, synaptophysin has 
also been associated with neurofibrillary tangle burdens(Revuelta et al., 2008) and 
presynaptic accumulation of α-synuclein(Kramer and Schulz-Schaeffer, 
2007)(Schulz-Schaeffer, 2010). 
As a presynaptic modulator for neurotransmission, Cannabinoid CB1 receptors are 
likely to be involved in synaptic functions. For instance, chronic treatment of 
cannabinoid agonist WIN55-212,2 in rat model was able to up-regulate 
synaptophysin expression in the hippocampus as well as cerebellum(Tagliaferro 
et al., 2006), indicating the potential role of cannabinoids stimulating neural 
plasticity and synaptic communication. In this study, the association between BA9 
CB1 receptor and synaptophysin may further support a potential role of CB1 
receptors in modulating synaptic signaling functions in Lewy body dementias.  
Beside the potential association with synaptic deficits, this study also indicates a 
possible correlation of CB1 receptors with senile plaque burdens. In BA9, patients 
with moderate or severe deposition of plaques showed a tendency of CB1 loss, and 
significant decrease of CB1 was observed in patients with moderate plaque 
burdens compared to those with sparse plaques. This result suggests that reduction 
of CB1 receptor density might be induced under amyloid plaque pathology, or on 
the other hand might contribute to the formation of amyloid plaques. 
In conclusion, this is the first study characterizing the status of Cannabinoid CB1 
receptors in frontal and temporal cortex of both PDD and DLB patients. Results 
indicate that PDD patients may suffer from greater damage of temporal cortex 
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CB1 receptors and frontal synaptic function compared to DLB and controls. CB1 
receptors may serve as therapeutic targets for synaptic dysfunctions and burden of 
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Effects of Cannabinoid CB1 Receptors on Muscarinic Receptor –
Modulated Amyloid Precursor Protein Processing in SH-SY5Y 
Neuroblastoma Cell Line 
9.1 Introduction 
As one of the major neuropathological hallmarks of Alzheimer’s disease (AD), 
Aβ are proteolytic derivatives of amyloid precursor protein (APP). In AD, the 
cleavage of APP by β- and γ-secretases releasing Aβ can be abnormally up-
regulated. Hence Aβ aggregates in the extracellular environment of 
neurons(Vassar et al., 1999), impairing neuronal function and inducing 
neurotoxicity. Alternatively, proteolysis of APP by α- and γ-secretases cleaves 
within the Aβ domain and releases a soluble N-terminal fragment sAPPα. 
Promotion of this pathway is considered ‘non-amyloidogenic’ ie against Aβ 
pathology, as it decreases the production of Aβ peptides. Furthermore,the APP 
metabolite sAPPα exhibits multiple neuroprotective roles, such as increasing 
neurotrophic factor release(Corrigan et al., 2011)(Clarriset al., 1997), promoting 
neurogenesis and neuronal differentiation(Turner et al., 2003)(Kwak et al., 
2006)(Caillé et al., 2004), sustaining synaptic plasticity as well as suppressing 
neurotoxicity and apoptosis(Furukawa and Mattson, 1998). 
Activation of Muscarinic M1/M3 receptors and their downstream MAPK-ERK 
related pathways has been reported to promote the non-amyloidogenic cleavage of 
APP, resulting in up-regulated sAPPα production and suppressed β-secretase 
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activity(Nitsch, 1996)(Fisher, 2007)(Hock et al., 2000)(Gu et al., 2003).Similaly, 
stimulation of Cannabinoid CB1 receptors have also been suggested to be 
neuroprotective against Aβ-induced neurotoxicity, with underlying mechanisms 
related to activation of MAPK(Milton, 2002), GSK-3β(Aso et al., 2012), PPAR-
γ(Fakhfouri et al., 2012) or Wnt/β-catenin pathway(Esposito et al., 
2006b).However, these studies have not investigated whether CB1 receptor 
activation/inhibition can influence the level of specific APP cleavage metabolites, 
such as sAPPα secretion. 
Furthermore, interactions between muscarinic receptors and Cannabinoid 
CB1receptors may play a role in cognitive function. While in animal experiments 
Muscarinic M1/M3 antagonists cause impairment of learning and memory 
(Calhoun and Smith, 1968)(Flood and Cherkin, 1986)(Broks et al., 1988), such 
impairments can be attenuated with co-treatment of CB1receptor inverse 
agonists(de Bruin et al., 2010)(Takahashi et al., 2005)(Rabbani et al., 
2012)(Dillon et al., 2011). Moreover, CB1receptor inverse agonists can produce 
synergistic memory-enhancing effect with cholinesterase inhibitors(Wise et al., 
2007)(Lange et al., 2010).These studies suggest that the co-administration of CB1 
antagonist/inverse agonist with cholinergic-enhancing medications might be 
promising for the treatment of cognitive and memory deficits in dementia 
patients.Yet it remains unclear whether CB1 inverse agonists may also affect APP 




In this study, we aim to explore whether co-administration of Cannabinoid 
CB1antagonists/inverse agonists may affect muscarinic receptor-mediated APP 
processing, or in other words, whether CB1 inverse agonists may shift muscarinic 
receptor-promoted non-amyloidogenic APP cleavage toward amyloidogenic 
direction. As a common downstream pathway of cannabinoid and muscarinic 
receptors, the role of MAPK-ERK was explored as a potential underlying 
mechanism. Neutral CB1 antagonist was tested as a negative control.  
The major research objective of this project is to investigate whether CB1 inverse 
agonists may shift muscarinic receptor-mediated non-amyloidogenic APP 
cleavage toward the amyloidogenic direction. Hypotheses of this project include: 
1) Muscarinic receptor agonist Carbachol (CCh) up-regulates basal sAPPα 
secretion via MAPK/ERK related mechanism; 
- CCh up-regulates basal sAPPα secretion in SH-SY5Y cell line 
- CCh-induced sAPPα up-regulation can be blocked by muscarinic 
antagonist Atropine 
- CCh-induced sAPPα up-regulation can be blocked by ERK inhibitor 
PD98059 
 
2) CB1 inverse agonists (AM251, AM281, LY320,135) attenuate Carbachol-
induced sAPPα up-regulation; 
3) CB1 inverse agonists suppress Carbachol-induced sAPPα up-regulation via 
MAPK/ERK-related mechanism, or: 
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 CCh-induced ERK phosphorylation can be suppressed by CB1 inverse 
agonists; 
4) The suppressive effect on Carbachol-induced sAPPα up-regulation was 
related to inverse activation of CB1 receptors, instead of neutral blocking, 
or: 
CB1 neutral antagonist NESS0327 cannot attenuate Carbachol-induced 
sAPPα up-regulation; 
5) Cannabinoid CB1 inverse agonists do not directly block muscarinic 
receptors, or: 
The binding of [
3
H]N-methylscopolamine with muscarinic receptors 
cannot be abolished by addition of AM251, AM281 or LY320,135. 
 
9.2 Materials and methods 
9.2.1 Cell culture in SH-SY5Y neuroblastoma cell line 
Human neuroblastoma SH-SY5Y cell line was grown with 1:1 mixture of DMEM 
and Ham’s F12 medium, with addition of 10% (vol/vol) fetal bovine serum, 1% 
pen strep and 1% NEEA. Cell monolayer culture dishes and plates were incubated 
in 95% air, 5% CO2 humidified incubator. For conditioned cell treatment, serum-
free medium was prepared from 1:1 mixture of DMEM and Ham’s F12 Medium. 
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Stock solutions of chemicals were prepared in either dH2O or Dimethyl Sulfoxide 
(DMSO) and diluted with the serum-free culture media at indicated 
concentrations upon time of treatment. DMSO at the final concentrations used (< 
0.1% vol/vol) did not affect any of the parameters tested.As described in Chapter 
6.2.3, levels of sAPPα in serum-free medium were measured with VIVASPIN 
technique (Sartorius) following manufacturer’s protocols. 
9.2.2 Neurochemical measurements using Western Blot and 
chemiluminescence imaging 
After treatments, protein samples from cell monolayers and/or culture medium 
were boiled with Laemmli buffer and separated on 10% SDS-PAGE gels, 
transferred onto nitrocellulose membranes using iBlot™ Gel Transfer Device 
(Invitrogen Life Science Technologies)and incubated at 4°Covernight with 
respective primary antibodies. Blots of cell lysates were stripped and reblotted 









Table 9.1 Antibodies for Western blot 
Primary Antibodies for immunoblots 
Primary Antibodies Species Dilution Supplier 
Anti-Aβ 1-16 (6E10) Mouse 1:1000 Covance 
Anti-phospho-p42/44 
MAPK (ERK1/2) 
Mouse 1:1000 Cell Signaling 
Anti-p42/44 MAPK 
(ERK1/2) 
Rabbit 1:1000 Cell Signaling 
Anti-CB1 Rabbit 1:1000 Sigma 
Anti-M1 Rabbit 1:1000 Millipore 
Anti-M3 Rabbit 1:1000 Millipore 
Anti-β-actin Mouse 1:5000 Sigma 
Secondary Antibodies for immunoblots 
Secondary Antibodies Species Dilution Supplier 
Anti-mouse-HRP Goat 1:5000 Jackson 





9.2.3 Chemiluminescence image acquisition and data analysis 
Chemiluminescence acquisition of Western blot images was performed using 
Alliance 4.7 Chemiluminescence Documentation System (UVItec, Cambridge). 
Analysis of Western blot images was performed with UVIsoft Image 
quantification software (Uvitec Cambridge, UK) by calculating relative densities 
of immunoreactive bands, which were expressed as arbitrary units and normalized 
to control bands. Controls treated with vehicle and processed in parallel with 
other conditioned treatments were included in every blot. 
SPSS 13.0 software (SPSS Inc., USA) was used for statistical analyses. Data were 
tested for normality using Kolmogorov–Smirnov tests, with selection of 
parametric or non-parametric tests for comparisons of variables between groups 
or correlations of variables based on normality of data. Statistical analysis was 
performed using one-way analysis of variance (One-way ANOVA). Null 
hypotheses were rejected at p < 0.05. 
 
9.3 Results 
9.3.1 Both Cannabinoid CB1 and Muscarinic M1/M3 receptors are expressed 
in SH-SY5Y cell line 
The expressions of both Muscarinic M1/M3 receptors and Cannabinoid CB1 
receptors have been previously described in human SH-SY5Y neuroblastoma cell 
line (Adem et al., 1987)(Klegeris et al., 2003). In this study, we verify the 
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existence of Muscarinic M1/M3 and Cannabinoid CB1 receptors in wild-type SH-
SY5Y neuroblastoma cell line.  
 
Figure 9.1 Expression of muscarinic and cannabinoid receptors in SH-SY5Y 
neuroblastoma cell line. M1 receptor expression was detected at ~60kDa using 
anti-muscarinic acetylcholine receptor M1 rabbit polyclonal primary antibody 
(AB5164, Millipore).M3 receptor expression was detected at ~65kDa using anti-
muscarinic acetylcholine receptor M3 rabbit polyclonal primary antibody 
(AB9018, Millipore). CB1 receptor expression was detected at ~60kDa using anti-
CB1 rabbit polyclonal primary antibody (C8985, Sigma-Aldrich Co., USA) 
 
9.3.2 Muscarinic receptor agonist Carbachol (CCh) induced sAPPα up-
regulation is related to activation of muscarinic receptors and ERK 
9.3.2.1 Carbachol up-regulates basal sAPPα secretion in SH-SY5Y cell line 
Carbachol works as Muscarinic M1 and M3 receptor agonist(Haraguchi and 
Rodbell, 1991). Atropine works as non-selective muscarinic receptor antagonist.  
Carbachol treatments (0.1~ 10μM) were conditioned on SH-SY5Y cells for 4hrs 
to test its dose-dependent effect on basal sAPPα secretion. Atropine was used to 
confirm whether CCh mediates sAPPα secretion via muscarinic receptor 
activation-related mechanism.  
 138 
 
Anti-APP 6E10 primary antibody (Covance, SIG-39320) was used to detect the 
soluble APP metabolite sAPPα in medium proteins, because 6E10 antibody reacts 
with amino acid residue 1-16 of β-amyloid peptide, a sequence that is present on 
sAPPα but not sAPPβ. Cell lysate samples were immunoblotted with anti-β actin 
antibody. Quantification of sAPPα expression is normalized as fold expression of 
the vehicle-treated cells from the same experiment. 
As shown in Figure 9.2, Carbachol induced dose-dependent up-regulation of 
basal sAPPα secretion in SH-SY5Y cell line, reaching significance at 1μM (One-
way ANOVA, p<0.05). 10μM Atropine was able to abolish 10μM CCh-induced 
significant increase of basal sAPPαsecretion, indicating that CCh modulates APP 




Figure 9.2 Effects of cholinergic stimulation and inhibition on sAPPα 
secretion in SH-SY5Y wild-type cell line. Cells were exposed to vehicle, 
Carbachol (0.1~10μM), Carbachol + Atropine (10μM+10μM) for 4hrs. Proteins 
secreted into the conditioned media were collected, processed with VIVASPIN 
and subjected to Western blot for sAPPα. The blot results were quantified using 
Uvitec as described in Chapter 6. Data are expressed as means ± S.E.M. (n = 
3~4). *, significant difference, p < 0.05 (compared with control cells). 
 
9.3.2.2 Stimulation of muscarinic receptors up-regulates ERK phosphorylation 
Carbachol treatments (0.1~10μM) were conditioned on SH-SY5Y cells to test the 
effect of M1 and M3 receptor activation on ERK1/2 phosphorylation.  
Upon time of treatment, cell medium of SH-SY5Y neuroblastoma cells grown on 
petri dishes was replaced with serum-free medium and incubated for 2hrs, 
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followed by Carbachol treatment for respective length of time (0, 15mins, 1hr, 
2hrs). Upon each timepoint, cell lysates were collected and immunoblotted with 
phosphor-ERK1/2 (pp42) and total ERK1/2 (p42) primary antibodies.  
As shown in Figure 9.3, Carbachol significantly enhanced phosphorylation of 
ERK1/2 at 15mins, while total ERK1/2 remain unchanged, which is consistent 
with previous knowledge(Kim et al., 1999)(Canet-Aviles et al., 2002). 
 
 
Figure 9.3 Effects of cholinergic stimulation on ERK phosphorylation in SH-
SY5Y wild-type cell line. Cells were exposed to 10μM Carbachol for respective 
time points. Lysed cells were subjected to Western blot for phosphor-ERK and 
total ERK.  
 
9.3.2.3 Carbachol-induced sAPPα secretion is related to ERK pathway 
PD98059 was used as a MAP kinase kinase inhibitor, specifically inhibiting ERK-
related phosphorylation kinase activity and suppressing ERK 
phosphorylation(Alessi et al., 1995). Carbachol treatments (with or without 
PD98059) were conditioned on SH-SY5Y cells for 4hrs to test its effect on basal 
sAPPα secretion.  
 141 
 
As shown in Figure 9.4, 10μM Carbachol significantly up-regulated basal sAPPα 
secretion in SH-SY5Y wildtype cells.10μM PD98059 was able to abolish this 
significant increase, indicating that the process of CCh modulating APP cleavage 
is related to ERK activation.  
 
Figure 9.4 Effects of cholinergic stimulation plus ERK inhibition on sAPPα 
secretion in SH-SY5Y wild-type cell line. Cells were exposed to vehicle, 
PD98059 (10μM) for 2hrs, followed by addition of Carbachol (10μM) for another 
2hrs. Proteins secreted into the conditioned media were collected, processed with 
VIVASPIN and subjected to Western blot for sAPPα. The blot results were 
quantified using Uvitec as described in Chapter 6. Data are expressed as means ±




9.3.3 MTS assay of Cannabinoid CB1 inverse agonists/neutral antagonists 
SH-SY5Y cells were grown on 96-well plates and treated in duplicates with 
respective doses of CB1 inverse agonists AM251/AM281/LY320,135 and CB1 
neutral antagonist NESS0327. Viability of cells was measured using CellTiter 
96® AQueous One Solution Cell Proliferation Assay (Promega, USA). Optical 
density was measured at 490nm using BioTek™ Epoch™ Microplate 
Spectrophotometer (Thermo Fisher Scientific Inc.). 
As shown in Figure 9.5, significant reduction of cell viability was induced by 
concentrations of AM251 at 30μM and NESS0327 at 1μM. AM281 and 
LY320,135 was relatively well tolerated.  
 
Figure 9.5: SH-SY5Y cell viability after CB1 inverse agonists/neutral 
antagonist treatment. Cells were treated with different concentrations of AM251, 
AM281, LY320,135 and NESS0327, and cell viability was measured using MTS 
assay. MTS absorbance readings were normalized to respective control wells 





9.3.4 CB1 inverse agonists inhibit Carbachol-induced sAPPα up-regulation as 
well as Erk phosphorylation in a dose-dependent manner  
9.3.4.1 CB1 inverse agonists inhibit Carbachol-induced sAPPα up-regulation in a 
dose-dependent manner 
Three structurally different Cannabinoid CB1 inverse agonists, AM251/AM281, 
LY320,135 were applied as parallel experiments to eliminate the possibility of 
structure-specific effects. SH-SY5Y cells were incubated with CB1 inverse 
agonists treatments for 2hrs, subsequently added with 10mM CCh (1:1000vol/vol, 
final 10μM) and incubated for another 2hrs.  
As shown in Figure 9.6, 9.7 and 9.8, co-administration of Cannabinoid 
antagonist/inverse agonist AM251/AM281/LY320,135 dose-dependently 
inhibited CCh-induced sAPPα secretion. The significant sAPPα increase was 




Figure 9.6 Effects of cholinergic stimulation plus Cannabinoid CB1 inverse 
agonism (AM251) on sAPPα secretion in SH-SY5Y wild-type cell line. Cells 
were exposed to vehicle or AM251 (1, 10μM) for 2hrs, followed by addition of 
Carbachol (10μM) for another 2hrs. Proteins secreted into the conditioned media 
were collected, processed with VIVASPIN and subjected to Western blot for 
sAPPα. The blot results were quantified using Uvitec as described in Chapter 6. 






Figure 9.7 Effects of cholinergic stimulation plus Cannabinoid CB1 inverse 
agonism (AM281) on sAPPα secretion in SH-SY5Y wild-type cell line. Cells 
were exposed to vehicle or AM281 (1,10μM) for 2hrs, followed by addition of 
Carbachol (10μM) for another 2hrs. Proteins secreted into the conditioned media 
were collected, processed with VIVASPIN and subjected to Western blot for 
sAPPα. The blot results were quantified using Uvitec as described in Chapter 6. 







Figure 9.8  Effects of cholinergic stimulation plus Cannabinoid CB1 inverse 
agonism (LY320,135) on sAPPα secretion in SH-SY5Y wild-type cell line. 
Cells were exposed to vehicle or LY320,135 (1,10μM) for 2hrs, followed by 
addition of Carbachol (10μM) for another 2hrs. Proteins secreted into the 
conditioned media were collected, processed with VIVASPIN and subjected to 
Western blot for sAPPα. The blot results were quantified using Uvitec as 
described in Chapter 6. Data are expressed as means ± S.E.M. (n = 3). *, 






9.3.4.2 CB1 inverse agonist AM251 inhibits Carbachol-induced ERK 
phosphorylation in a dose-dependent manner 
SH-SY5Y neuroblastoma cells grown on 6-well plates were incubated in serum-
free medium for 2hrs, and treated with Carbachol (with or without AM251) for 
15mins. Cell lysates were immunoblotted with phosphor-ERK1/2 (pp42) and total 
ERK1/2 (p42) primary antibodies.  
As shown in Figure 9.9, 10μM Carbachol significantly up-regulated Erk 
phosphorylation. Co-administration of Cannabinoid antagonist/inverse agonist 
AM251 dose-dependently inhibited CCh-induced Erk phosphorylation. The 





Figure 9.9 Effects of cholinergic stimulation plus Cannabinoid CB1 inverse 
agonism on ERK phosphorylation in SH-SY5Y wild-type cell line. Cells were 
exposed to vehicle or AM251 (1,10μM) for 2hrs, followed by addition of 
Carbachol (10μM) for another 15mins. Lysed cells were subjected to Western blot 
for phospho-ERK and total ERK. The blot results were quantified using Uvitec as 
described in Chapter 6. Data are expressed as means ± S.E.M. (n=3~4). *, 
significant difference, p < 0.05. 
 
9.3.5 CB1 neutral antagonist NESS0327 does not inhibit Carbachol-induced 
sAPPα 
Neutral CB1 antagonist NESS0327 was tested as a negative control as it does not 
have inverse activation property. As shown in Figure 9.10, 10μM Carbachol 
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significantly up-regulated basal sAPPα secretion in SH-SY5Y wildtype cells, 
while co-administration of CB1 neutral antagonist NESS0327 failed to suppress 
CCh-mediated increase of sAPPα secretion even at neurotoxic concentration of 
5μM. 
 
Figure 9.10 Effects of cholinergic stimulation plus Cannabinoid CB1 neutral 
antagonism on sAPPα secretion in SH-SY5Y wild-type cell line. Cells were 
exposed to vehicle or NESS0327 (0.01, 0.1, 1, 5μM) for 2hrs, followed by 
addition of Carbachol (10μM) for another 2hrs. Proteins secreted into the 
conditioned media were collected, processed with VIVASPIN and subjected to 
Western blot for sAPPα. The blot results were quantified using Uvitec as 
described in Chapter 6. Data are expressed as means ± S.E.M. (n=3~4). *, 





9.3.6 CB1 antagonists/inverse agonists do not directly block muscarinic 
receptors 
To confirm that previous inhibitory effect of Cannabinoid CB1 inverse agonists on 
sAPPα  was not due to direct blocking of muscarinic receptor signaling, the 




H]NMS) was used to 
measure the surface binding of muscarinic receptors in SH-SY5Y cells.[
3
H]NMS 
exclusively labels receptors on the cell surface while [
3
H]Scopolamine measures 
total receptor density including both internalized and surface receptors(Molina-
Holgado et al., 2003). In this study, no purpose of studying muscarinic receptor 
uncoupling or internalization was intended, nor was the incubation time (3hrs) 
long enough to induce significant receptor internalization, thus only cell surface 
binding was measured with [
3
H]NMS. 
SH-SY5Y cells were grown on 6-well plates. Upon time of treatment, cell 
medium was aspirated and cell monolayers were gently washed twice with ice-
cold PBS. Conditioned treatments were prepared and added into respective wells 
(3nM [
3
H]NMS in PBS as 100% control, with or without indicated concentrations 
of Atropine, AM251, AM281, LY320,135). Each concentration of chemicals was 
incubated and measured in duplicates. Cell plates were incubated on 4 °C water 
bath for 3hrs.  
Upon end of treatment, the radioactive medium is aspirated and discarded as 
radioactive waste. Cell monolayers were gently washed twice with ice-cold PBS, 
and subsequently incubated with 500 μl 1% Triton-PBS on ice for 30mins to 
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allow cell lysis.  Afterwards, lysed cell solution from each well was gently 
pipetted and collected into respective scintillant tube. Each well was washed again 
with 500μl ice-cold 1% Triton PBS and then collected into its tube. Each 
scintillant tube was added with 2ml of Optiphase 'Hisafe' 2 Liquid Scintillation 
Oil, tightly capped and labeled and measured for radioactivity using scintillant 
machine as described in Chapter 6.2. 
 










As shown in Figure 9.11, the selective muscarinic antagonist Atropine blocked 
surface binding of [
3
H]NMS onto muscarinic receptors by 50% at as low 
concentration as 10nM, and stabilized surface reading at around 10%~15% of 
control at higher concentrations, indicating highly specific and effective blocking. 
Three CB1 receptor inverse agoists, AM251, AM281 and LY320,135 were unable 
to alter surface binding of [
3
H]NMS from 10nM to high concentration of 10μM. 
In conclusion, Cannabinoid CB1 receptor selective inverse agonists do not directly 





Figure 9.11 Effects of muscarinic/Cannabinoid CB1 blockers on [
3
H]NMS 
binding in SH-SY5Y neuroblastoma cell line. Cells were treated with 3nM 
[
3
H]NMS as duplicates, while co-incubated with respective concentrations of 
Atropine, AM251, AM281, and LY320,135. Radioactivity was measured using 
scintillation assay. DPM readings were normalized to respective control wells 
treated with 3nM [
3
H]NMS alone. Error bars represent means±S.E.M. *. p<0.05; 
**, p<0.01, significant difference. 
 
9.3.7 Summary of results 
In the SH-SY5Y neuroblastoma cell line which contains both Cannabinoid CB1 
and Muscarinic M1/M3 receptors, selective activation of postsynaptic Muscarinic 
M1/M3 receptors increases basal sAPPα via ERK1/2-related pathways. The co-
administration of cannabinoid inverse agonists was able to abolish the significant 
increase of sAPPα secretion induced by muscarinic agonist Carbachol. The 
modulatory effect of cannabinoid antagonists/inverse agonists on the CCh-sAPPα 
pathway was not via direct blockade of muscarinic receptors, but related to the 
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CB1 inverse agonists such as Rimonabant have been widely studied for their 
therapeutic potential against obesity and metabolic disorders (as described in 
Chapter 4.4.1), although several large-scale clinical trials have pointed out serious 
psychiatric side effects such as inducing severe depression and suicidal 
intentions(Després et al., 2005)(Topol et al. 2010)(Motaghedi et al. 2011)(Gruber 
et al., 1996), which led to its clinical discontinuation. More recently, instead of 
inverse agonist, neutral CB1receptor antagonists without inverse agonizing effect 
have been developed showing promising potential in modulating obesity and 
metabolism disorders(Silvestri and Di Marzo, 2012).  
While it has been suggested that the co-administration of CB1inverse agonists 
with cholinergic-enhancing medications (e.g.  Acetylcholinesterases) might 
provide synergistic therapeutic effects on cognitive and memory deficits in 
dementia patients, the potential hazardous side-effects may occur as well, we may 
suspect, if cannabinoid antagonists/inverse agonists are applied to dementia 
patients as a co-treatment medication with ChEIs. 
Our study provides novel evidence against such co-administrationof CB1 inverse 
agonists with cholinergic enhancements. The neuroprotective up-regulation of 
sAPPα by muscarinic agonist can be suppressed by CB1 inverse agonists. In other 
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words, when co-administrated with CB1 inverse agonist, the promotion of non-
amyloidogenic APP cleavage by muscarinic receptor activation can be somehow 
compromised, losing its neuroprotective effect against Aβ pathology. Though CB1 
inverse agonists have been observed to improve memory functions in animal 
models, using them as co-treatment with cholinergic medications for dementia 
patients with neuropathological Aβ burdens may render these patients less well 
protected against Aβ neurotoxicity, or even increase the possibility of amyloid 
plaque formation. 
In conclusion, my study further explored the interaction between two 
neurotransmitter systems at molecular level, that co-treatment with CB1 receptor 
inverse agonists may abolish the neuroprotective effect of muscarinic enhancers 
promoting α-secretase pathway of amyloid APP processing.The neutral CB1 
antagonist, on the other hand, does not suppress muscarinic-mediated non-
amyloidogenic APP processing, thus may serve as a better option to be co-
administrated with cholinergic enhancement therapy. 
Future work for this study may also include exploring the changes of other 
markers in APP processing pathway (ADAM10, ADAM17, BACE, Aβ40/42) as 
well as other signaling molecules involved (PKC, Gi/o and Gq proteins) under the 
influence of CB1 antagonists/inverse agonists.  
One limitation of this study is that the effect of CB1 selective agonists on sAPPα 
secretion in SH-SY5Y cells was not included. While multiple synthetic or phyto- 
cannabinoids have been tested in various animal models, one practical difficulty 
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of testing them or their structural analogues using in vitro cell models is that they 
are very hydrophobic. Water solubilization of cannabinoid agonists often require 
substances like ethanol, polyethylene glycol or Tween(Pertwee et al., 2000), 
which are likely to induce pharmacological consequences as a solvent. 
Nevertheless, even if dissolved in the above agents under precise calculation, 
cannabinoids may still precipitate and adhere to container surface, which makes 
the preparation and maintenance of consistent dosage rather difficult(Martin et al., 
2006). In this study, two commercially available CB1 selective agonists from 
Tocris, ACEA (in ethanol) and ACPA (in Tocrisolve™ 100), have been tested in 
preliminary experiments to measure their potential stimulatory effect on sAPPα in 
SH-SY5Y cells. Unfortunately, results were inconsistent between different 
batches of chemicals. Therefore, potential modulatory role of CB1 agonists on 
amyloid APP processing remains to be explored using in vitro cell models, if 























General Conclusions and Future Work 
10.1 Contributions of my work 
In this thesis, two neuromodulatory systems, the histaminergic and cannabinoid, 
as well as two subtypes of dementia, vascular dementia and Lewy body dementia, 
were studied. Using radioligand binding and Western blotting assay, the status of 
Histaminergic H3 and Cannabinoid CB1 receptors in postmortem brain tissues 
from longitudinally assessed  cohorts was measured, compared between disease 
groups and statistically correlated with available biochemical and physiological 
parameters of patients in the database. Apart from postmortem tissue studies, 
neuroblastoma cell line was used to investigate the impact of cannabinoid ligands 
on the regulatory molecular signaling pathways related to dementia pathology. 











Table 10.  Major findings 
 Histaminergic H3 receptor Cannabinoid CB1 receptor 
AD  Chapter 9: 
In SH-SY5Y neuroblastoma cell line, 
co-administration of Cannabinoid CB1 
inverse agonists abolished the enhanced 
sAPPα secretion induced by muscarinic 
agonist Carbachol via CB1 receptor-
related mechanism. This modulatory 
effect was not via direct blockade of 
muscarinic receptors, but related to 
inverse activation of Cannabinoid CB1 








Histaminergic H3 receptors are 
relatively preserved in SIVD and 
mixed dementia patients compared 
to controls in the frontal cortex, 
hippocampus and anterior 
cingulate. In the anterior cingulate 
region, H3 density in SIVD group is 




dementia group. Higher frontal 
cortex H3 receptor expression was 





 Chapter 8: 
PDD group showed lower CB1 
expression in BA21 and reduced 
synaptophysin level in BA9. BA9 CB1 
expression is significantly correlated 
with synaptophysin level. Patients with 
a heavier burden of senile plaques 
showed a tendency of CB1 loss. 
 
 
As described in Chapter 7, the findings of preserved Histaminergic  H3 receptor 
status in SIVD and mixed dementia patients provided new insights on the 
potential role of histaminergic H3 receptors as therapeutic targets in different 
subtypes of dementia other than Alzheimer’s (Medhurst et al., 2009). No 
significant alterations of H3 receptor densities were observed in disease groups 
(SIVD and mixed dementia) compared to non-demented controls, which are 
similar to the AD cohort results, indicating the preservation of Histaminergic H3 
receptors in these two major types of dementia. Notably, the significant 
correlation observed in AD cohort between frontal cortex H3 expression and pre-
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death cognitive function is also present in the results of SIVD and mixed 
dementia patients. My study further explored the neurochemical alterations in the 
brains of vascular dementia and mixed dementia patients, and expanded the 
potential application field of Histaminergic H3 receptor as a therapeutic target to 
enhance cognitive performances in dementia patients. 
Neurochemical characterization of Cannabinoid CB1 receptors (Chapter 8) in this 
thesis also provides innovative knowledge of CB1 status in postmortem brains of 
Lewy body dementia. While previous studies mostly focused on the status of CB1 
in AD (Chapter 4.2), this thesis for the first time examined the expression level 
of Cannabinoid CB1 receptors in post-mortem Lewy body dementia brains. While 
precise diagnosis of Lewy body dementia subtypes currently remains unfeasible, 
the significantly lower level of CB1 receptors in the temporal lobe of PDD 
compared to both DLB and control support the potential value of CB1 receptors as 
neurochemical marker for better diagnosis and treatment of Lewy body dementia. 
Also, associations of CB1 with synaptic markers and amyloid plaques are 
supportive of CB1 receptors as potential modulator of synaptic transmission and 
Aβ pathology in neurodegenerative diseases. 
My study in Chapter 9 added to the knowledge of a potential regulatory 
mechanism of Cannabinoid CB1 receptor ligands on amyloid APP protein 
cleavage and Aβ deposition. Experiments using three different CB1 selective 
inverse agonists pointed out the potential amyloidogenic influences of CB1 
inverse agonism, especially on the non-amyloidogenic APP cleavage process 
regulated by Muscarinic M1/M3 receptors. This might serve as an alarming 
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message against clinical strategies of utilizing CB1 inverse agonists as cognitive 
and memory enhancers which have been implied in a number of animal studies, 
especially those indicating that CB1 inverse agonists were able to ameliorate 
muscarinic antagonism-induced memory deficits (de Bruin et al., 2010)(Rabbani 
et al., 2012)(Wise et al., 2007)(Lange et al., 2010). 
The potential association of CB1 with amyloid pathology was studied in both 
Chapter 8 and 9. In the postmortem study of CB1 in Chapter 8, patients with 
heavier senile plaque burdens had a tendency of CB1 reduction, indicating 
possibilities of CB1 receptor being affected by plaques, or CB1 loss playing a role 
in the formation of plaque pathology.  This implication together with the 
amyloidogenic effect of CB1 inverse agonists observed in Chapter 9 seemed to be 
supportive of the notion, that the blockade or inverse activation of CB1 receptor 
signaling is linked to higher vulnerability of dementia patients to Aβ neurotoxicity.  
Thus, even though the neutral CB1 antagonist NESS 0327 did not alter sAPPα 
secretion, it is still necessary to assess its influence on other APP proteolysis 
markers. 
 
10.2 Limitations of my work 
Postmortem tissue condition: As postmortem brain samples were used for 
characterization of receptor binding affinity and density, most of the 
neurochemical data are not representative of the entire disease population and can 
only be used to describe patients in very late stage of disease with relatively 
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severe symptoms. The viability of histaminergic or cannabinoid receptors 
working as therapeutic targets remains to be tested using animal study or clinical 
trials, if applicable.   
Limited sample size: Neurochemical measurement of receptors was performed 
using ≤ 30 patients in each diagnosis group (Chapter 7 and 8). To restrict cohort 
effects caused by limited sample availability, experiments and statistical analysis 
were performed using samples matched for demographic and disease variables 
(e.g. age, gender, post-mortem delay). In Chapter 8, after statistical exploration 
of correlations between CB1 receptors and neurochemical parameters, only 
significant correlations (BA9 CB1 and synaptophysin) with moderate to strong 
strength (Pearson’s Correlation, p<0.05, r≥0.3 or ≤-0.3) were listed. Larger 
cohorts are needed in order to confirm any correlations or group differences listed 
in this thesis. 
Usage of neuroblastoma cell line: As a cloned subline derived from SK-N-SH 
cells, SH-SY5Y neuroblastoma cell line undergoes long time of storage and 
proliferations that require frequent passages. In this process, alterations of 
biochemical properties may occur and affect cell-cell interactions and signaling 
pathways. To avoid cell stress or neurotoxic events during cell growth and 
maintain cell condition consistency, only passage 14~20 of SH-SY5Y cells were 
used for chemical treatments and biochemical measurements. Furthermore, the 
physiological in vivo conditions in the central nervous system can not be 
represented by in vitro SH-SY5Y cell line which originated from bone marrow of 
a neuroblastoma patient, even though SH-SY5Y cell line has been widely used in 
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neurological experiments as it is characterized to express of multiple 
neurotransmitter systems and related downstream signaling pathways.  
10.3 Future work 
CB1 as potential therapeutic target for treating depression in LBD:  
Extensive numbers of studies have supported the role of CB1 receptors in 
modulating depression. Reduction of CB1 receptors has been observed in 
depressed or stressed animal and human cases(Parolaro et al., 2010), and 
pharmacological knockout or blockade of CB1 receptor in animals induce passive, 
depressed behavior in models of stress(Martin et al., 2002)(Steiner et al., 
2007)(Mato et al., 2007). On the other hand, enhancement of cannabinoid 
signaling in animal models(Kathuria et al., 2003)(Macr   and Laviola, 2004)(Jiang, 
2005)(Hill and Gorzalka, 2005)(Gobbi, 2005)  showed anti-depressant properties. 
CB1 receptors have also been reported to enhance anxiety-related behaviors,(Dono 
and Currie, 2012)(Zarrindast et al., 2010), while cannabinoids or FAAH inhibitor 
produce anxiolytic and panicolytic responses(Casarotto et al., 2012)(Rubino et al., 
2008b)(Campos and Guimarães, 2009)(Zarrindast et al., 2010)(Rubino et al., 
2008a). 
Although CB1 density was not significantly correlated to any physiological 
parameters related to depression in this thesis, a general trend of CB1 receptor 
decrease can be shown in frontal BA9 region of LBD groups compared to 
controls, while in BA21 PDD group showed a significant reduction. These results 
corresponded to previous knowledge that, as previously described in Chapter 
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3.2.1, LBD patients may suffer from even worse neuropsychiatric symptoms (e.g. 
depression, anxiety) than AD patients. Further postmortem studies in larger 
cohorts are required to identify potential links between CB1 and depression in 
Lewy body dementia patients, in order to evaluate the potential role of CB1 
receptors providing neuroprotection not only against Aβ pathology, but also with 
anti-depressant and anti-psychotic efficacy. 
 
Mechanism of interaction between CB1 and muscarinic receptors in SH-SY5Y 
cells 
Although it has been suggested in Chapter 9 that the interaction between CB1 (Gi 
protein coupled receptors) and muscarinic receptors (Gq protein coupled receptors) 
may involve downstream modulation of MAPK/ERK pathway, the underlying 
mechanisms of their interaction at receptor level remain unclear.  
According to Quitterer et al.(Quitterer and Lohse, 1999), the stimulation of Gi 
protein coupled receptors may enhance Gq  protein mediated downstream signals 
(e.g. inositol phosphate), because the released Gβγ complex from Gi protein can 
subsequently interact with Gq coupled receptors, facilitate the GTP/GDP 
exchange on the Gαq subunit, and thus promote downstream signaling pathways 
of Gq proteins.  
As only CB1 inverse agonists were tested in this project, it remains unclear 
whether the inverse agonism of the Gi protein coupled CB1 receptors will produce 
the opposite effect, which is inhibiting the GTP/GDP exchange on the Gαq 
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subunit, therefore suppressing downstream signaling pathways of Gq proteins. It 
could be suspected that, by inhibiting the GTP/GDP exchange on the Gαq subunit 
of muscarinic receptors, CB1 inverse agonists may decrease the dissociation of Gq 
protein from muscarinic receptors and therefore suppress Gq protein-related 
subsequent downstream signaling. 
In order to investigate whether this mechanism is involved in the CB1-muscarinic 
interaction observed in this project, the following experimental designs can be 
tested: 
(I) To investigate whether the modulatory effect of CB1 inverse agonists is 
dependent on Gi receptor inverse activation, the SH-SY5Y cells are to be 
pre-incubated with the Gi subunit inhibitor Pertussis Toxin (PTX) before 
subsequent treatment of Carbachol/Carbachol + AM251. In this way, they 
can be compared with cells that received parallel treatments but without 
pre-incubation of PTX. 
Hypotheses include: (1) PTX does not alter Carbachol-induced sAPPα up-
regulation, i.e. there is no significant difference of sAPPα expression in 
CCh-treated cells with and without pre-incubation of PTX. (2) The effect 
of AM251 attenuating CCh-induced sAPPα up-regulation can be 
abolished by pre-treatment of PTX, i.e. cells treated with CCh + AM251 
as well as pre-incubation of PTX show significantly higher level of sAPPα 
compared with cells treated with CCh + AM251 but without pre-
incubation of PTX. 
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(II) To investigate whether CB1 inverse agonists inhibit the GTP/GDP 
exchange on the Gαq subunits of muscarinic receptors, 
[
3
H]Pirenzipine/Carbachol competition assay is to be applied to SH-SY5Y 
cells treated with Carbachol/Carbachol + AM251 according to the 
previously published protocol(Flynn et al., 1991).  
The rationale for this assay is described below:  
When the muscarinic receptors are associated with Gq proteins (i.e. the 
GDP attached to the Gαq subunit is not replaced by GTP), Carbachol is 
able to bind with muscarinic receptors with high affinity; when the 
muscarinic receptors are ‘uncoupled’ with Gq proteins (i.e. the GDP 
attached to the Gαq subunit is replaced by GTP, triggering the dissociation 
of G-proteins from muscarinic receptors), Carbachol binds with 
muscarinic receptors with relatively low affinity. [
3
H]Pirenzipine is able to 
bind with muscarinic receptors in both situations. Cells under each 
specific type of treatment will be divided into two parallel groups, both 
incubated with a constant concentration of [
3
H]Pirenzipine and increasing 
doses of Carbachol, but with Guanylyl-imidodiphosphate (GppNHp) 
added into one of the parallel groups. As a non-hydrolysable analogue of 
GTP, the binding of GppNHp with Gαq subunit will prevent the 
hydrolysation of GTP back into GDP, thus is able to restrain the re-
association of G-proteins with muscarinic receptors, keeping the receptors 
‘uncoupled’ from G-proteins. In this way, muscarinic receptors in this 
parallel group can only bind with Carbachol with low affinity, and the 
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radioactive readings caused by [
3
H]Pirenzipine binding will be higher 
compared to cells without treatment of GppNHp, as [
3
H]Pirenzipine 
becomes relatively more competitive than Carbachol in binding with these 
‘uncoupled’ muscarinic receptors. In other words, higher concentration of 
Carbachol is required to maintain the same radioactive reading in the 
presence of GppNHp.  
When the radioactive bindings of [
3
H]Pirenzipine are plotted against log-
transformed Carbachol concentrations, a horizontal ‘shift’ can be observed 
between the curves of two parallel groups under the same treatment but 
with/without GppNHp.  For each binding curve, the inhibitory constants of 
Carbachol with (Ki) or without GppNHp (KiG) can be calculated according 
to the concentration of Carbachol suppressing 50% of the maximum 
[
3
H]Pirenzipine reading (IC50), and the ratio of KiG/Ki is used to 
characterize the magnitude of the ‘shift’. The magnitude of this ‘shift’ is 
related to the original coupling status between muscarinic receptors and G-
proteins. The more receptors coupled to G-proteins, the greater magnitude 
of the ‘shift’ will be observed, and the greater KiG/Ki will be. If the 
receptors are already uncoupled from G-proteins before the addition of 
GppNHp, little or no ‘shift’ will be observed, and the KiG/Ki ratio will 
almost equal 1. 
If CB1 inverse agonists are able to suppress the GTP/GDP exchange of 
muscarinic receptors as we previously suspected, the binding curves of 
SH-SY5Y cells treated with CCh + AM251/CCh + AM251 + GppNHp 
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will present a greater ‘shift’ compared with cells treated with CCh/CCh + 
GppNHp. So the hypothesCBis is: the KiG/Ki ratio of cells treated with 
CCh + AM251 will be significantly larger than the KiG/Ki ratio of cells 
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